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Abstract 
 
            Doxorubicin (DOX) blocks the autophagic flux in cardiomyocytes by inhibiting 
lysosome acidification. The acidic pH of lysosomes is maintained by the V-ATPase pump.  
NAD+ is an essential cofactor for the maintenance of cellular homeostasis. DOX treatment 
significantly depletes the NAD+ levels in cardiomyocytes. This study investigated the 
potential of the NAD+ precursor, nicotinamide mononucleotide (NMN), in preventing DOX-
induced cardiotoxicity. DOX induced cell injury and altered the lysosomal pH of H9c2 cells, 
an in vitro model of cardiomyocytes. These effects of DOX were attenuated by NMN. The 
protection conferred by NMN was offset by inhibition of V-ATPase activity with bafilomycin 
A. Furthermore, NMN prevented the DOX induced hyperacetylation of the V-ATPase 
subunit ATP6V0d1, a critical protein involved in the maintenance of V-ATPase activity. In 
summary, NMN protects cardiomyocytes from DOX induced toxicity by maintaining the pH 
of lysosomes. Thus, NMN holds potential in combating the deleterious impacts of 
Doxorubicin on the heart.  
Keywords: ATP6V0d1; cardiotoxicity; doxorubicin; lysosome; NAD+; NMN; V-ATPase  
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Summary for Lay Audience 
 
           Cancer is one of the leading causes of death worldwide. Nearly 1 in 2 Canadians 
develop cancer during their lifetime. The harsh reality of cancer does not end with its onset. 
The devastating dark side of the available treatment options like chemotherapy impacts the 
patient’s quality of life. Doxorubicin, the chemotherapy antibiotic, is routinely used for the 
treatment of multiple cancers. Its deadliest side effect is heart injury, which leads to heart 
failure. In fact, over 50% of the childhood cancer survivors develop heart disease in the later 
stages of their life. Doxorubicin impairs a cellular process known as autophagy in heart cells. 
Autophagy or cellular recycling is a self-eating process by which the damaged components in 
the cells can be degraded and recycled. This recycling process occurs in designated recycling 
centres or specialized compartments called lysosomes in the cell. Efficient functioning of 
lysosomes is rendered by their acidic nature or low internal pH. This helps the lysosomal 
proteins to break down the cellular debris. The low pH in lysosomes is achieved with the help 
of a cellular pump called V-ATPase positioned on the lysosomal membrane. V-ATPase 
transports protons into the lysosome and maintains optimal pH. Doxorubicin increases the pH 
of lysosomes and it could most likely be by damaging the V-ATPase pump, but the exact 
mechanism remains unknown.  
            NAD+ is a critical molecule in the body which is required for many essential 
reactions in the cell. Doxorubicin decreases the natural levels of NAD+ in the body and 
compromises the normal functioning of the cell. NAD+ depletion effects the lysosome 
function too. This study aims to identify the impact of Doxorubicin treatment on the pH of 
lysosomes and the V-ATPase pump in the heart cells. Nicotinamide mononucleotide (NMN) 
is a vitamin B3 derivative and NAD+ supplement that provides many essential benefits to the 
body. The role of NMN in preventing the harmful effects of Doxorubicin have been 
investigated in this study. The results indicate that NMN has promising potential in protecting 
the heart from the side effects of Doxorubicin.  
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Chapter 1 
1 Introduction 
 
            Cancer is the leading cause of death in Canada and the Canadian Cancer Society 
estimates more than 80,000 deaths and 225,000 newly diagnosed cases in the country in 
2020. Lung, breast, prostate and colorectal cancers together account for about nearly half of 
the newly diagnosed cases in Canada. Though the incidence is higher in population aged 
more than 50, it can affect at any age (1). Chemotherapy is most often used as the treatment 
option alone or in combination with radiation, surgery etc. The word “chemotherapy” was 
coined by the renowned German chemist Paul Ehrlich in the early 1900’s to address the use 
of chemicals to treat disease. Nitrogen mustard was one of the earliest chemotherapy agents 
used for cancer treatment. Even though the initial hype stirred considerable interest in the 
drug, it soon subsided as remissions occurred in treated patients (2).  
           Cancer chemotherapy is a double-edged sword attacking both tumour cells and normal 
cells alike. This could lead to deleterious side effects and so deciphering the mechanistic 
action of these drugs in malignant and non-malignant cells is of high importance. 
Doxorubicin is a commonly administered chemotherapy agent worldwide and it is used in 
adult and paediatric cancer patients alike with commendable recovery rates. Due to its 
toxicity profile and bright red appearance, Doxorubicin has been notoriously nicknamed as 
the “Red Devil”. Alongside the common side effects of most chemotherapeutic antibiotics, 
like nausea, vomiting, mouth sores and alopecia, Doxorubicin could elicit irreversible 
damage to the heart as well. Though widely studied, the mechanisms of Doxorubicin 
triggered cardiac injury remains elusive. Numerous drug candidates have entered clinical 
trials to combat the side effects of Doxorubicin, but none of them have been completely 
successful so far (3). This study explores the mechanism and potential of Nicotinamide 
mononucleotide, a vitamin B3 derivative of natural origin, in preventing the cardiotoxic side 
effects of Doxorubicin in an in vitro model of disease.   
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1.1 Anthracyclines 
 
            The efforts to investigate potential anti-neoplastic agents from soil microbes by the 
Italian company, Farmitalia Research Laboratories, led to the discovery of the first 
anthracycline antibiotic. Prof. Di Marco and his team isolated and purified a red pigment 
from a spore forming Streptomyces peucetius found in the soil near the Castel del Monte on 
the shores of the Adriatic Sea. This drug showed promising anti-tumor activity and was 
named Daunomycin. A similar drug with identical physicochemical properties was isolated 
by a French research group led by Maurice Dubost from Streptomyces coeruliorubidus at 
about the same time and was named Rubidomycin. The name daunorubicin was hence 
internationally adopted to avoid conflicts and by late 1960’s it was clinically introduced for 
cancer treatment (4). The success of the new drug soon initiated the drive for development of 
analogues with higher therapeutic index.  
            Chemical mutagenesis of Streptomyces peucetius led to the development of a variant 
which produced another anthracycline antibiotic, Doxorubicin. Epirubicin and Idarubicin 
were synthetically developed from Doxorubicin and Daunorubicin, respectively. Epirubicin 
exerts lower cardiotoxic effects and Idarubicin is more lipophilic compared to their parent 
drugs. Several new drugs were later added to this group and the list remains inexhaustive 
(Table 1). Though anthracyclines showed promise in their efficacy for the treatment of 
cancer, the toxic side effects mainly related to cardiac health were soon reported in patients, 
raising concerns. Despite this, anthracycline therapy remains an important cancer treatment 
regimen after nearly 50 decades of its discovery and is included in the World Health 
Organization’s list of essential medicines. Daunorubicin, Doxorubicin, Epirubicin and 
Idarubicin are the commonly used anthracyclines in the clinics at present (Figure 1.1) (5,6).  
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Table 1: Anthracycline drugs 
Anthracycline Trade Name Indications 
Daunorubicin  Daunoxome, Cerubidine ® acute lymphocytic leukemia 
Doxorubicin Doxil®, Rubex ® solid tumors, hematoligic 
malignancies 
Epirubicin Ellence axillary node metastases after 
surgical breast cancer resection 
Idarubicin Idamycin acute myeloid leukemia 
Valrubicin Valstar, Valtaxin bladder carcinoma 
Aldoxorubicin - Under investigation 
Annamycin - Under investigation 
Plicamycin Mithracin testicular cancer  
Sabarubicin - Under investigation 
Zoptarelin doxorubicin - Under investigation 
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Figure 1.1: Chemical Structure of Anthracyclines. The four commonly used anthracycline 
drugs Doxorubicin, Daunorubicin, Idarubicin and Epirubicin. 
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1.2 Doxorubicin 
 
            Doxorubicin (DOX) is produced as a secondary metabolite from the bacterial strain 
Streptomyces peucetius var. caesius. It was initially named Adriamycin, in recognition of the 
Adriatic Sea, from where daunomycin, the first anti-cancer anthracycline was discovered (4). 
DOX is extensively used  in the treatment of solid tumors of the breast, lung, and bladder, 
cervical cancer, lymphomas and sarcomas, in combination with other drugs such as 
cyclophosphamide, paclitaxel etc. (7). Attributed to the efficiency of the drug in 
chemotherapy treatment, the global DOX market is forecasted to be about 1.38 billion USD 
by the year 2024, with North America contributing the major share followed by Europe and 
Asia Pacific (8).  
           The chemical structure of DOX is comprised of a characteristic anthracycline 
tetracyclic ring with an adjacent quinone-hydroquinone group linked to a sugar moiety, 
daunosamine, by a glycosidic bond. The presence of a methoxy group attached to the 
tetracyclic ring and methyl group attached to daunosamine distinguishes DOX from its 
analogues (9). As the oral bioavailability of DOX is very low (< 1%) due to limited intestinal 
absorption, it is intravenously administered and undergoes rapid tissue distribution and slow 
elimination (10). DOX rapidly exits the circulation and accumulates in tissues, mostly in the 
liver. It does not cross the blood-brain barrier despite being highly penetrative. The 
metabolism of DOX begins in the liver and transforms to its main active immediate 
metabolite Doxorubicinol in a NADPH dependent conversion by carbonyl reducing enzymes. 
The sugar components of DOX and Doxorubicinol undergoes acid catalysed hydrolysis to 
form the aglycones, doxorubicinone and doxorubicinolone, respectively. These metabolites 
are then excreted in urine and faeces (11). 
            More than 2000 analogues of DOX have been synthesized and have been researched 
for their anti-neoplastic potential. Efforts to develop more efficient and less toxic analogues 
led to the use of liposomal encapsulation technology. Doxorubicin was the first anti-cancer 
drug to reach clinical trials as a lipid-based formulation. Liposomes are mostly confined to 
the vascular system, and limits the exposure of doxorubicin to the myocardial cells having 
tight junctions. Since the tumour cells are not tightly joined, the liposomal drug can exit the 
circulation and accumulate in these cells. Phospholipids of the liposomes are derived from 
natural sources like egg yolk and soya bean and can be eliminated from the circulation within 
a few hours by plasma protein opsonization. But this short half-life limits its potential to a 
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certain extent. To overcome this, polymers such as polyethylene glycol (PEG), ganglioside, 
and cerebroside sulphate that resisted opsonization were incorporated to the liposomal 
formulation. Pegylated- liposomal DOX is now available under the trade name Doxil®    and 
has a circulatory half-life of 3-4 days. Adding a PEG molecule however, because of its large 
size, could limit the entry of liposome to the tumour cells and decrease the accumulation of 
DOX. Also, since Doxil® has high affinity towards the skin, it causes a dose-limiting hand-
foot syndrome (HFS) in nearly 50% of patients treated with the drug. Non-pegylated versions 
of liposomal encapsulated DOX such as Myocet® have been introduced into the North 
American market but is relatively expensive (12). 
 
1.2.1 Anti-cancer mechanism   
 
            The chemotherapeutic efficacy of DOX is attributed to its interaction with DNA, 
topoisomerase inhibition and generation of reactive oxygen species (ROS) (13). It covalently 
interacts with double stranded DNA by intercalating between the bases. At the maximum 
saturation level, one molecule of DOX intercalates into every fifth base-pair of DNA. A 
partial B to A-DNA transition occurs in the structure which accounts for the anti-cancer 
activity of the drug (14). Topoisomerases are ubiquitous enzymes involved in the replication, 
transcription, recombination, repair, and chromatin modelling. DOX inhibits topoisomerases 
and disrupts the repair and replication mechanisms in the nucleus (15,16).  
            DOX also undergoes reduction to form a semiquinone radical by cellular oxidases, 
which reacts with oxygen, generating ROS and exerts toxic effects on the cancer cells or gets 
oxidised back by redox cycling (17). The drug interacts with the plasma proteins too and gets 
reduced resulting in the formation of the highly potent hydroxyl radicals. Apoptosis is 
triggered in cells when the repair process in response to DNA damage fails. DOX treatment 
activates the p53 pathway and downregulates Bcl-2 expression subsequently activating the 
effector caspases, the mediators of apoptosis (11).  
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Figure 1.2: Anti-cancer mechanism of Doxorubicin. DOX exerts its anti-cancer properties 
by intercalating into the DNA, inhibiting the topoisomerases and generating free radicals.          
 
1.3 Doxorubicin Cardiotoxicity 
 
            The adverse effects of DOX and other anthracycline analogues on cardiac health were 
reported by late 1960’s (18). But still, even after nearly 5 decades, it remains a key player in 
the chemotherapeutic regime amidst the outcomes. Occurrence of cardiac complications is 
estimated in one among eight DOX-treated patients (19). The cardiotoxic events associated 
with DOX could be acute which occurs during or immediately after treatment, or chronic, 
occurring within a year (early-onset) or several years post-treatment (late-onset). Acute DOX 
cardiotoxicity is reversible, and manifestations could include reduced contractility, 
pericarditis, myocarditis, sinus tachycardia, ST-T wave changes and decreased QRS complex 
amplitude. Early-onset chronic complications include dilated cardiomyopathy with reduced 
ejection fraction, electrical conduction changes, valve damage and reduced contractility. 
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Late-onset cardiotoxicity is often a silent killer, is irreversible and progresses to heart failure.  
The progressive nature of chronic DOX cardiotoxicity places the cancer survivors receiving 
the medication at immense risk and the prognosis remains poor (19–21).  
    
1.3.1 Pathophysiology 
 
            Dilated cardiac chambers, reduced ventricular ejection fractions, diastolic 
dysfunction, changes in the ventricular wall thickness are some of the pathological 
occurrences associated with Doxorubicin treatment. Structural deformities such as 
myocardial interstitial fibrosis, vacuolated cardiomyocytes, nuclear-chromatin 
disorganization, distended sarcoplasmic reticulum, damaged mitochondria and increased 
number of autophagic vacuoles are evident as well (20,22).  
 
1.3.2 Risk Factors  
 
            Age, gender, cumulative dose, genetic predispositions, and pre-existing medical 
history are all considered as risk factors leading to DOX induced cardiomyopathy. Nearly 
48% of the patients receiving a cumulative dose of more than 700 mg/m2 of DOX end up 
having congestive heart failure (20,21,23). More than 57% childhood cancer survivors have 
been reported to develop chronic cardiac complications (24). Female gender is a further risk 
factor in paediatric cancer patients while adult males are considered at more risk than their 
counterparts (25). Individuals having variants of several genes have been associated with 
increased risk of Anthracycline-induced toxicity as well (26). The epidemiology of DOX 
induced cardiomyopathy stresses the importance of clinically relevant preventive treatment 
strategies and hence research into elucidating the pathogenesis of DOX cardiotoxicity is 
important and would lead to the identification of more molecular targets for drug 
development (Figure 1.3). 
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Figure 1.3: Risk factors associated with DOX-induced cardiomyopathy. 
Incidence of DOX related toxicity and cardiomyopathy increases with age (children and 
aged), gender, cumulative dose (>700 mg/m2), genetic make-up of the individual and pre-
existing health conditions. 
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1.3.3 Mechanisms of Cardiotoxicity 
 
            Accumulation of DOX in the myocardium, coupled with the low levels of endogenous 
antioxidants within the heart exponentiate the potent cardiotoxic effects of the drug. DOX 
rapidly enters the cells by passive diffusion and accumulates in intracellular compartments. 
The nuclear concentration of DOX is 50-fold more than in the cytoplasm and nearly 2% of 
the cytosolic load is distributed among other organelles such as Golgi, lysosomes and 
mitochondria (11). Multiple mechanisms have been identified in the emergence and 
progression of DOX cardiotoxicity. Increased oxidative stress, disruption of calcium 
homeostasis, apoptosis activation, DNA damage and autophagic dysregulation have been 
implicated in the advancement of cardiac dysfunction (27).  
            DOX gets reduced to a semiquinone radical by cellular oxidases, Nitric oxide 
synthase (NOS) and nicotinamide adenine dinucleotide phosphate-oxidase (NOX), which 
then reacts with oxygen and generates free radicals. These radicals damage DNA and attack 
the membrane lipids. DOX’s high affinity toward the cardiac-specific inner mitochondrial 
membrane lipid, cardiolipin, disrupts the electron transport chain resulting in reduced ATP 
production and increased mitochondrial ROS generation (28).  
            Cardiac muscle contractility is mediated by the excitation-contraction coupling in 
cardiomyocytes regulated by the entry of calcium into the cytoplasm. The intracellular 
calcium then induces the release of calcium from the sarcoplasmic reticulum (SR) by binding 
to the ryanodine receptor. This process is termed as calcium-induced calcium release (CICR) 
and it enables the contraction of cardiomyocytes. The uptake of calcium by the sarcoplasmic 
reticulum calcium transport ATPase (SERCA) decreases the cytoplasmic calcium levels and 
induces relaxation of cardiomyocytes. DOX-induces dysregulation of intracellular calcium 
levels by several mechanisms. DOX binds to the ryanodine receptor and inhibits functioning. 
It can also interact with luminal calcium binding proteins and the membranous SERCA pump 
of the SR, and modify their actions resulting in impaired calcium handling and contribute to 
the ROS pool (29).  
            The activation of the tumour suppressor p53 pathway by DOX stimulates apoptosis 
and NF-κB activation induces inflammation and cytokine storm in cardiomyocytes (30). 
DOX treatment also induced early stages of autophagy and suppressed the later stages 
resulting in the inhibition of autophagic flux and accumulation of autophagosome generating 
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oxidative stress in cardiomyocytes (22). The role of ROS in the progressive decline of cardiac 
health with DOX treatment has been well studied and documented (31). ROS mediated 
disruptions in nuclear, lysosomal, mitochondrial, and endoplasmic reticulum events have an 
evident role in the etiology of DOX cardiotoxicity (32). This study focusses on the role of 
dysfunctional lysosomes in facilitating cardiomyocyte death.  
             
         
 
Figure 1.4: Doxorubicin induces Cardiomyocyte cell death. DOX-induced ROS 
generation coupled with low levels of antioxidants in the heart leads to oxidative stress and 
effects the cardiomyocyte organelles.  
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1.4 Autophagy and Cardiovascular diseases 
 
            Under normal physiological conditions, ROS generation from multiple sources 
contribute to the induction of autophagy and the removal and recycling of damaged 
organelles and defective proteins within the cell. The cellular debris is sequestered into a 
double membraned vesicle, the autophagosome, in the endoplasmic reticulum. The loaded 
autophagosome then fuses with the lysosome which subsequently leads to the degradation of 
the debris by the lysosomal enzymes and is then released back into the cytosol (33).  
            The mammalian target of rapamycin complex 1 (mTORC1) and AMP-dependent 
protein Kinases (AMPK) are the two signalling mechanisms implied in the control of 
autophagy. mTORC1 signalling cascade is involved in numerous cellular processes 
regulating growth, based on the nutritional and environmental intimations. Nutrient 
starvation, cellular stress and certain growth factors negatively regulate mTORC1 and 
promotes the induction of autophagy (34). Slight increases in the levels of AMP, can be 
detected by AMPK which in turn phosphorylates many target proteins required for energy 
homeostasis in the cell. AMPK mediated phosphorylation deactivates the mTORC1 complex, 
thereby activating the autophagic machinery. AMPK also directly initiates autophagy via 
mTORC1 independent pathways (35).  
            Both these signalling pathways are involved in the phosphorylation of the upstream 
component of autophagy initiation, ULK1 (UNC 51 like kinase 1) kinase complex. mTORC1 
binds to ULK1 complex rendering it inactive, while AMPK phosphorylates it and promotes 
the downstream signalling (35–39). This serine/threonine kinase complex includes the 
proteins ULK1, FIP200 (focal adhesion kinase family interacting protein of size 200 kDa), 
ATG13 (autophagy related gene 13) and ATG101. The activated protein complex drives the 
single membrane phagophore formation by activating the VPS34 (vacuole protein sorting 34) 
complex comprised of class III phosphatidylinositol 3-kinase (PI3K), VPS34, VPS15 
(vacuole protein sorting 15), BECLIN 1 and ATG14 (autophagy related gene 14) (40). 
Interaction among the VPS34 complex components generates phosphatidylinositol 3-
phosphate (PI3P) promoting phagophore elongation and autophagosome formation. The 
ATG5-ATG12-ATG16L complex dimer then associates with the evolving phagophore and 
recruits lipidated LC3 (microtubule associated protein 1 light chain 3).  Once the 
autophagosome development is complete, the ATG5-ATG12-ATG16L complex dissociates, 
leaving the LC3 intact on the luminal and exterior regions of autophagosome. LC3 is 
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regarded to play a role in the selective uptake of components to be degraded into the 
autophagosome by interacting with molecules like p62/SQSTM1. This protein is a 
multifunctional adaptor and binds to ubiquitinated cargos that are directed for clearance (41–
44). Rab 7 (GTPase of the Ras-related protein in brain (Rab) family), SNARE complex 
(soluble N-ethylmaleimide sensitive fusion protein receptor) and lysosome-associated 
membrane proteins 1 and 2 (LAMP-1 and LAMP-2) along with other factors directs the 
autophagosome-lysosome fusion forming the autolysosome (45,46). The cargo loaded into 
the autolysosomes then undergoes degradation in the acidic lysosomal environment by the 
hydrolytic enzymes and the degraded products are recycled.  
            Impaired lysosome acidification has been implicated to be fatal in multiple cell types 
like neurons, hepatocytes, and cardiomyocytes (47–49). The acidic luminal pH (4.5-5) is vital 
for the maturation and hydrolytic activity of lysosomal enzymes and efficient lysosomal 
function. Even a slight increase in pH would be detrimental and could result in cell death. 
Lysosomes contain more than 60 degradative enzymes responsible for breaking down the 
unfolded proteins, damaged organelles, amino acids, and fatty acids. Myocytes being post-
mitotic cells, are considered mostly irreplaceable and are vulnerable to pathological changes. 
Absence of replication compel these cells to rely on the recycling processes for their survival. 
Hence lysosomal integrity and functional autophagy are crucial for the smooth functioning of 
cardiomyocytes. Depressed autophagy in cardiomyocytes leads to the accumulation of the 
ubiquitinated intracellular cargo meant to be recycled and increases ROS production (50).  
            Lysosomal dysfunction has been reported in several cardiac complications. Lysosome 
storage disorders (LSDs) manifest as hypertrophic and dilated cardiomyopathy, coronary 
artery disorders, and valve defects in the heart. Dysregulations in lysosome biogenesis also 
contribute towards the development of cardiovascular complications (51). Transcription 
factor EB (TFEB) regulates the expression of lysosomal proteins and the genes involved in 
lysosome biogenesis. Decreased expression of TFEB has been linked to cardiac 
proteinopathy and cardiomyocyte death (51). DOX-induced inhibition of lysosomal 
acidification blocks the autophagic flux in cardiomyocytes and led to the accumulation of 
autolysosomes in in vivo mice models (52). Stimulating basal autophagy have been reported 
to protect cardiomyocytes from DOX-induced toxicity probably by eliminating the 
dysfunctional mitochondria and other organelles and hence reducing ROS production (28).  
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Figure 1.5: Schematic representation of Autophagy. Autophagy begins with the formation 
of an initiation membrane, which develops into a phagophore and elongates to form an 
autophagosome carrying the cellular debris. Lysosome fuses with the autophagosome 
forming the autolysosome and the proteolytic enzymes within this structure breaks down the 
cargo which is then released into the cytosol and recycled. 
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1.5 V-ATPase 
 
            Intracellular pH maintenance is accomplished with the help of ion channels, receptors, 
transporters and pumps (53). The maintenance of the acidic pH gradient in the lysosomes is 
achieved through the activity of vacuolar ATPase (V-ATPase), an ATP dependent 
membranous proton pump highly conserved among eukaryotes. It was initially identified and 
characterised in the yeast, Saccharomyces cerevisiae and is structurally similar to the 
bacterial ATP synthase, F-ATPase (54). Apart from acidification of lysosomes and 
endosomes, plasma membrane V-ATPases are also involved in other functions such as sperm 
maturation and bone resorption (55). It has also been associated with cellular processes such 
as signalling, membrane fusion, membrane trafficking, protein degradation, nutrient 
homeostasis etc. (56). This multimeric protein has a cytosolic domain V1 and a membrane 
domain V0 that undergoes reversible coupling to transport protons into the lysosomal lumen. 
ATP hydrolysis occurs at the subunits of V1 domain which generates the energy required for 
the translocation of protons through the membrane bound V0 domain subunits. In yeast, low 
glucose, low pH and low salt concentrations prevents the assembly of the domains as a 
measure to conserve ATP and prevent energy expenditure. It has also been shown that 
increased extracellular pH prevents glucose mediated disassembly of V0 and V1 (57). 
Contrastingly, in mammalian cells, low glucose and amino acid starvation has shown to 
increase the V-ATPase activity probably to increase the autophagic flux and recycle amino 
acids within the cell (58).  
 
1.5.1 V-ATPase Structure 
 
            Mammalian V1 domain is water-soluble and comprised of 8 subunits A, B, C, D, E, F, 
G and H. The membrane embedded V0 domain subunits include a, c, c″, d, e, ATP6AP1 and 
ATP6AP2. Three copies each of A and B subunits of the cytosolic V1 are arranged as an 
alternating hexamer. The D and F subunit forms the rotating central stalk (rotor) of the V-
ATPase pump. The E and G subunits exist as three heterodimers forming the peripheral stalk 
(stator) connecting V1 to subunit a of V0. The conformational changes of the linker protein 
subunit H act as switch in controlling the reversible assembly of V1-V0 and prevents ATPase 
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activity of the pump. The hydrophobic c ring of V0 comprises of nine copies of c and one 
copy of c″ subunits each containing a single glutamate buried residue which undergoes 
reversible protonation to translocate protons into the lysosomal lumen. Subunit d links the 
proteolipid c ring to the rotating central stalk. The transmembrane subunit a binds to subunits 
H, C and the peripheral stalk in the intact V-ATPase pump. It conducts proton to the 
glutamate residues of the c ring and enables its exit at the luminal side via two hemi-channels 
facing the cytoplasmic and luminal side, respectively. Subunit e occupies an adjacent position 
to subunit a and is highly hydrophobic but its function in mammalian cell remains unknown. 
ATP6AP1 and ATP6AP2 are two transmembrane accessory proteins located within the c 
ring. ATP6AP1 acts as a regulatory protein and is involved in vesicular trafficking and bone 
resorption in osteoclasts. ATP6AP2 is a pro renin receptor and is thought to contribute to V-
ATPase mediated control of the renin-angiotensin pathway in regulating blood pressure and 
electrolyte balance (58–60).  
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Figure 1.6: Structure of mammalian V-ATPase. The mammalian V-ATPase pump has a 
membrane-embedded V0 domain and a cytosolic V1 domain. V1 has eight subunits (A-H) and 
V0 contains five subunits (a, c, c’, d, e). ATP6AP1 and ATP6AP2 are the accessory proteins 
within the c ring of V0. ATP hydrolysis at V1 generates the energy for the transport of protons 
into the lumen by the V0.   
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1.5.2 V-ATPase Isoforms 
 
            Multiple subunit isoforms of mammalian V-ATPase have been identified and 
characterised. Mammalian cells express four isoforms of subunit a and two each of subunits d 
and e of the V0 domain. There are three isoforms of  C and G of the V1 domain and two each 
of subunits B and E. V0a is an integral membrane protein of ∼110 kDa having a cytosolic N-
terminal and 9 transmembrane domains and is the largest subunit of the V0 domain. The 
targeting of V-ATPase to the membrane of different cell types is achieved by this subunit. 
Although ubiquitous, the expression of V0a1 is high in the brain, localised mainly on the pre-
synaptic membrane and synaptic vesicles and is implicated in the acidification of these 
vesicles. Neuronal cells and endothelium are enriched with V0a2 and it is found on the 
intracellular Golgi vesicles. Membranes of lysosomes, osteoclasts and secretory vesicles of 
pancreatic islet cells express V0a3 and this isoform is crucial mediator of the bone resorption 
mechanism. V0a4 is almost exclusive to the renal cells of the kidney and also found in the 
inner ear and epididymis (61,62). V0d1 occurs ubiquitously and V0d2 is predominantly 
expressed in the kidney, osteoclasts, and lungs. It is nearly 40 kDa and is considered as one of 
the linker proteins between the V0 and V1 domain at the central stalk of the pump. 
Heterologous overexpression of this subunit improves the coupling efficiency of the V-
ATPase pump (63). Two isoforms of the V0e subunits exist, e1 being ubiquitous and e2 found 
in the brain. V1B1 and V1B2 are of nearly 56 kDa, the former being expressed in the kidney, 
ear and lung and the latter being ubiquitous with enriched expression in the osteoclasts. V1C 
is around 42 kDa and among its isoforms, C1 is ubiquitous. C2a and C2b are specific to lung 
and kidney, respectively. V1E has a molecular weight of 31 kDa and E1 is testis specific 
while E2 is ubiquitous.V1G occurs as a heterodimer with V1E and is of 13 kDa. Among its 
isoforms, the ubiquitous one is V1G1. V1G2 and V1G3 are expressed in the brain and kidney 
respectively (54,64). 
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1.5.3 V-ATPase proton transport mechanism  
 
            The proton transport mechanism begins with the assembly of the V1 and V0 domains. 
ATP hydrolysis occurs at the catalytic sites of the A3B3 hexamer enabling the rotation of the 
central stalk. The proteolipid c ring attached to the central stalk rotates relative to subunit a 
held stationary by the peripheral stalk. Protons enter subunit a through the cytoplasmic hemi-
channel and protonates the glutamate residues on the c ring which rotates and reaches the 
luminal hemi-channel. Deprotonation of these residues occur by interaction with a conserved 
arginine residue of subunit a releasing a proton to the hemi-channel facing the luminal side. 
For every three ATPs hydrolysed at V1 domain, ten protons are translocated to the lumen 
(58,60,65–68). Numerous studies have established the importance of functional V-ATPase in 
maintaining the autophagic flux, the measure of autophagic degradation activity in the cell. 
The outcomes observed with the loss of V-ATPase activity and inhibition of lysosome 
acidification are the formation of enlarged autolysosomes resembling yeast vacuoles mutant 
for peptidases (69,70).   
 
1.5.4 V-ATPase Reversible assembly in mammals 
             Upon various stimuli such as environmental stress and nutrient depletion, cellular 
homeostasis must be maintained in mammals by upregulating the recycling capacity of the 
cells. The rate of autophagy or autophagic flux is enhanced and lysosomal degradation of 
ubiquitinated cellular debris is increased so that the amino acids, fatty acids, and other 
molecules are available back in the cytoplasm so that it can be metabolised to generate 
energy. Based on the requirement, the V-ATPase pump acidifies the lysosomes to achieve 
optimal recycling capacity. The rotation driven proton pumping mechanism of V-ATPase is 
tightly regulated by the reversible dissociation of the V1 and V0 domains. Though initially 
described in yeast, a similar mechanism applies to mammalian cells as well.  
            In response to glucose starvation in mammals, AMPK activity and the 
phosphatidylinositol 3-kinase/Protein kinase B (PI3K/Akt) signalling pathway activate the 
assembly of V0 and V1 domains, increasing the proton transport and re-establishing the 
optimal lysosomal pH. During disassembly, V1C dissociates from the V1 domain and 
separates it from V0. The structure of the C resembles a collar and a transient phosphorylation 
at this subunit is predicted to control its interaction with V1E, V1G and V0a. V1H undergoes a 
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conformational change to inhibit the ATP hydrolysis at V1 preventing ATP expenditure and 
blocks the proton transport at V0. V1, devoid of the C subunit is found in the cytoplasm as a 
free water-soluble protein and V0 remains membrane bound (Figure 1.7) (58,67,71).  
 
 
 
 
 
 
 
Figure 1.7: V-ATPase activity is tightly regulated by reversible disassociation of V0 and 
V1 domains. Upon nutrient depletion, subunit C detaches from cytoplasmic V1 domain, and 
separates it from the membrane bound V0 domain. Subunit H undergoes a conformational 
change and hinders ATP hydrolysis at V1 and hence conserves energy. The rotation of the 
stalk and proton transport at the V0a is stalled and the V-ATPase pump becomes inactive. 
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1.5.5 V-ATPase inhibitors 
 
            Malfunctional V-ATPase activity have been reported in multiple pathological 
conditions conferring this ubiquitous pump the status of an attractive therapeutic target. A 
handful of V-ATPase inhibitors have so far been identified and are available in the market 
allowing researchers to further study the scope of V-ATPase modulation that could be 
translated to clinical settings. Bafilomycin A and concanamycin A were the first among a 
handful to be identified in the 1980’s and was isolated from the Streptomyces sp. These 
pleco-macrolide antibiotic V-ATPase inhibitors are characterised by a 6-membered 
hemiacetal ring connected to the macrolactone ring by a C3 spacer. The macrolactone 
antibiotic archazolid also inhibits V-ATPase and is highly toxic to cells. Archazolid A has a 
macrocyclic lactone ring with a thiazole side chain and is produced by the myxobacteria 
Archangium gephyra and Cystobacter violaceus. Bafilomycin A, concanamycin A and 
archazolid inhibits V-ATPase by binding specifically to the subunit c of V0 (72–74).  
            A relatively new class of V-ATPase inhibitors were identified in the late 1990’s and 
they shared a common benzolactone enamide structure. Salicylihalamides, lobatamides, 
oximidines and apicularens belonged to this group and were isolated from natural micro-
organism sources. They were peculiar in their inability to inhibit V-ATPases of fungal origin. 
The benzolactone enamide apicularen binds to the interface of the subunits a and c of the 
membrane embedded V0 domain stalling the proton transport. Natural compounds of plant 
origin, Diphyllin and Celangulin V also inhibited V-ATPase activity in vitro. Though the 
mechanism of inhibition by Diphyllin has not been well characterised, Celangulin V binds to 
the subunits a, H, and B of V-ATPase (73,75–77).  
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Figure 1.8: Structures of V-ATPase inhibitors. The V-ATPase inhibitory capabilities of 
Bafilomycin, Concanamycin, Archazolid and Apicularen have been characterised and are 
used as pharmacological tools for studying lysosome function and autophagy 
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1.5.6 Bafilomycin A 
 
            Bafilomycin A disrupts autophagy by inhibiting lysosomal acidification and 
autophagosome-lysosome fusion. It was quite recently reported that the Bafilomycin A 
inhibits the autophagosome-lysosome fusion via its effects on the Ca2+ transporter pumps. 
The proton transport mechanism of V-ATPase is blocked by this macrolide by binding to the 
subunit c of the V0 domain. Other ATPases such as ATP2A/SERCA are also moderately 
inhibited by this antibiotic (78–80). Though its clinical use is limited because of toxicity, 
Bafilomycin A serves as an important pharmacological tool to study autophagy.  
 
 
             
Figure 1.9: Bafilomycin A inhibits the proton transport mechanism of V-ATPase. 
Bafilomycin A inhibits V-ATPase pump and prevents lysosome acidification and stalls the 
autophagic machinery in cells. 
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1.5.7 V-ATPase activity in the heart 
 
            Decreased V-ATPase activity have been linked to contractile dysfunction in 
cardiomyocytes. Excessive lipid accumulation impairs the endosomal pump activity and 
leads to cardiac insulin resistance in rodents and human cardiomyocytes. It is speculated that 
lipids induce V-ATPase disassembly into V0 and V1 and migration of V1 into the cytoplasm. 
In response, the long chain fatty acid transporter CD36 in the heart, stimulated by insulin,  
translocates to sarcolemma from endosomes leading to further increase in up-take and storage 
of triacylgycerols and elicit insulin resistance (49). Proper regulation of endosomal pH is 
necessary for directed translocation of glucose transporters (GLUT) in the heart as well. 
Restoring V-ATPase activity has been hence considered as a promising strategy to combat 
lipid-induced cardiomyopathy (81).  
            High-density lipoproteins (HDL) are generally considered as the “good” cholesterol 
as it aids in reverse cholesterol transport from the tissues to the liver for elimination. The 
anti-atherogenic property of HDL is mainly attributed to its major component Apolipoprotein 
A1 (ApoA1). ApoA1 accepts the cell cholesterol with the help of the cell membrane protein 
ATP-binding cassette A1 (ABCA1) and generates nascent HDL. Activation of ApoA1 occurs 
when it’s lipidated causing the N-terminal to unfold and spontaneously react with the 
membrane lipids and release nascent HDL from the cell. ABCA1 mediated recruitment of V-
ATPase to the cell surface promotes acidification increasing the membrane lipid fluidity and 
N-terminal unfolding of ApoA1. Thus V-ATPase modulation helps in HDL biogenesis and 
cholesterol efflux and provides protection from coronary heart disease (82). DOX treatment 
has been reported to disrupt the basal autophagic flux by inhibiting the lysosomal V-ATPase 
activity and decreased cardiomyocyte cell survival. Increased lysosomal pH in 
cardiomyocytes led to the accumulation of autolysosomes and exacerbated oxidative stress 
(83),(52). Though DOX mediated inhibition of lysosomal acidification has been proved in 
cardiomyocyte lysosomes, the exact mechanism of V-ATPase modulation remains unclear.  
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1.6 Nicotinamide Adenine Dinucleotide (NAD+) 
 
            NAD+ is a major coenzyme present within all living cells and is involved in various 
essential cellular processes. It was discovered in boiled yeast extracts more than a century 
ago by Sir Arthur Harden. NAD+, its phosphorylated form NADP, and reduced forms NADH 
and NADPH, are important cofactors in the energy producing and metabolic processes within 
the cell (84). NAD+ pools within the mammalian cell occur in the cytosol, nucleus, 
mitochondria, endoplasmic reticulum and Golgi network (85).  NAD+ consuming enzymes in 
the cell are sirtuins, poly ADP-ribose polymerases (PARPs) and CD38/157 ectoenzymes. 
Seven mammalian sirtuins have been identified till date and they are involved in many 
cellular pathways. These proteins are evolutionarily conserved and belong to class III protein 
deacetylase family, which are the only histone deacetylases requiring NAD+ for their 
activity. Sirtuins cleave NAD+ forming nicotinamide (NAM) and the acetyl group of the 
substrate protein is transferred to the ADP-ribose moiety of NAD+ producing O-acetyl-ADP-
ribose and the deacetylated substrate (86). The PARP family of proteins are involved in poly-
ADP ribosylation i.e., the transfer of ADP-ribose to target proteins. Members of this family 
are involved in many vital cellular processes such as DNA synthesis and repair, nucleic acid 
metabolism and chromatin structure modulation (87). CD38 and CD157 are considered as 
ectoenzymes, a family of enzymes having an extracellular catalytically active site. These 
proteins catalyse the conversion of NAD+ to cyclic ADP-ribose, an important secondary 
messenger in calcium signalling. They are mainly expressed in immune cells and are also 
involved in cell adhesion and migration (88). 
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Figure 1 10: Structure of NAD+. 
 
 
 
1.6.1 NAD+ Biosynthesis 
 
           The major precursors and intermediates involved in the biosynthesis of NAD+ are 
tryptophan, nicotinamide, nicotinic acid, nicotinamide riboside and nicotinamide 
mononucleotide. These are obtained either from the diet or by the intracellular NAD+ 
catabolism. The Preiss-Handler pathway utilizes the enzyme Nicotinic acid 
phosphoribosyltransferase (NaPRT) to convert dietary Nicotinic acid or Vitamin B3 to 
NaMN (Nicotinic acid mononucleotide). NaMN/NMN adenyltransferases (NMNATs) 
converts NaMN to nicotinic acid dinucleotide (NAAD). NAD+ is amidated from NAAD by 
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NAD+ synthetase enzyme (NADS). The de novo pathway involves the essential amino acid 
tryptophan which is metabolised to Quinolinic acid (QA) via the kynurenine pathway in the 
liver. It is then converted to NaMN by Quinolinic acid phosphoribosyltransferase (QAPRT) 
and then to NAD+ using the Preiss-Handler pathway. The contribution of the de novo 
pathway towards NAD+ pool in mammals is negligible as tryptophan metabolism contributes 
to other cellular processes as well. Mammalian NAD+ synthesis occurs mainly via the 
salvage pathway involving the conversion of Nicotinamide (NAM), produced from NAD+ 
consuming reactions, to Nicotinamide mononucletide (NMN) by the rate-limiting enzyme 
Nicotinamide phosphoribosyltransferase (NAMPT). NAM is the by-product of NAD+ 
breakdown by sirtuins, PARPs and CD38/157 ectoenzymes. NAMPT is also activated by 
AMPK, the autophagy stimulating kinase in cells. Nicotinamide Riboside (NR), a Vitamin 
B3 derivative, also contributes to the NMN pool by Nicotinamide riboside kinase (NRK) 
mediated enzymatic phosphorylation. Two isoforms of NRK have been discovered, the 
ubiquitously expressed NRK1 and the skeletal muscle specific NRK2. NMN is then 
converted to NAD+ by NMNAT. Three isoforms of NMNAT have been identified so far and 
they differ in their sub-cellular location and catalytic actions. The ubiquitously expressed 
NMNAT1 is predominantly found in the nucleus. NMNAT2 is mostly brain-specific and 
localised in the cytosol and Golgi compartments. NMNAT3 is mitochondrial specific, found 
in liver, heart, skeletal muscle and also in red blood cells (84,89–92).   
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Figure 1.11:  Schematic illustration of NAD+ biosynthesis in mammalian cells. 
NaPRT- Nicotinic acid phosphoribosyltransferase; NMNAT- NaMN/NMN 
adenyltransferases; NADS- NAD+ synthetase; QAPRT- Quinolinic acid 
phosphoribosyltransferase; NRK- Nicotinamide riboside kinase; NAMPT- Nicotinamide 
phosphoribosyltransferase (rate-limiting enzyme) (93). 
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1.6.2 NAD+ in the heart 
 
            The half-life of NAD+ in mammalian cells is around 10 hours with mitochondrial 
NAD+ accounting for nearly 70-75% of the total cellular content in heart cells (84). This is in 
consistence with the high energy demands of the heart. The levels of the Nicotinic acid 
converting enzyme NaPRT is low in heart and hence Nicotinamide mediated NAD+ 
biosynthesis is thought to be the predominant source of the co-enzyme. NAD+ depletion has 
been reported in multiple pathologies associated with the heart. Supplementing NAD+ has 
been reported to protect the heart in in vivo models of heart failure. Restoring NAD+ levels in 
the ischemic and hypertrophic heart prevents disease progression and decreases the risk of 
heart failure (94). Despite the promising therapeutic effect of NAD+ upregulation in the 
heart, the protective mechanism in various cardiovascular pathologies remains largely 
unanswered. Protein hyperacetylation in failing myocardial cells was attributed to the 
unavailability of NAD+ for sirtuin-mediated deacetylation. Altered energy metabolism and 
decreased NAD+ biosynthesis was also observed in models of failing heart. NAD+ 
precursors reduced the protein acetylation, restored the energy metabolism and increased the 
synthesis of NAD+ in the heart thereby preventing further damage to the organ (95).  
            The delicate balance between NAD+ synthesis and consumption in the cells are 
altered during pathological conditions. NAD+ levels in the cell increase during energy- 
limiting conditions such as fasting, calorific restriction, low glucose diets or exercise. High 
fat and high glucose diets as well as oxidative stress deplete NAD+ levels in the cell and 
affect downstream cellular processes (94). Boosting NAD+ levels has been reported to 
ameliorate multiple pathological conditions such as diabetes, cardiovascular diseases, 
neuropathies and age-related cellular dysfunction (96). NAD+ inhibition also blocks 
autophagic flux (97) and so maintaining the balance between the consumption and synthesis 
is essential for cellular integrity.  
             
1.6.3 Role of NAD+ in Autophagy 
             
            Autophagy plays a central role in maintaining cellular homeostasis particularly in 
post-mitotic cells like cardiomyocytes. NAD+ is essential for sustaining the basal autophagic 
machinery in these cells (98). NAD+ is reduced to NADH to facilitate cellular ATP 
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generation through glycolysis in the cytosol, and via the tricarboxylic acid cycle in the 
mitochondria. Imbalances in the NAD+/NADH ratio affect ATP generation and activate the 
AMPK pathway and autophagy. NAD+ can be phosphorylated to NADP+ and then get 
converted to NADPH which catalyses the formation of the antioxidant glutathione. Reduction 
in glutathione levels upsets the redox balance in the cell and activates AMPK. NAD+ 
depletion and ROS can impair the autophagic machinery by influencing post-translational 
modifications of autophagy-related proteins. During pathological conditions, PARPs and the 
CD38/157 ectoenzymes are hyperactivated, and consume the intracellular NAD+ pools 
leading to its depletion. PARPs consume nearly 10 - 20% of NAD+ within minutes of DNA 
damage.  Sirtuin activity is hence reduced and so are the deacetylation processes which are of 
crucial significance in the regulation of autophagy-related proteins, transcription factors and 
receptors. Acetylation of transcription factor EB (TFEB), the master regulator of lysosome 
biogenesis, has been linked to its inability to bind to DNA and negative regulation of 
lysosomal genes. Though acetylation and deacetylation related functional regulation of 
multiple other autophagic proteins such as ULK1 and ATG 3,7,5 and 12 have also been 
identified, the list does not tend to be exhaustive. PARP activation also inhibits mitochondrial 
ATP synthesis by inactivating sirtuins and induces autophagy by activating the AMPK 
pathway (85,99).  
 
1.6.4 Nicotinamide mononucleotide (NMN) 
 
              Nicotinamide mononucleotide (NMN) or Nicotinamide-1-ium-1-β-D-ribofuranoside 
5′-phosphate is an intermediate in the NAD+ biosynthesis pathway and it is formed by the 
reaction between nicotinamide (NAM), a phosphate group and a nucleoside containing a 
ribose moiety. NMN is also formed from NR by enzymatic phosphorylation (Figure 1.11). It 
has a molecular weight of 334.221 g/mol and exists as two anomers, alpha and beta, the latter 
being the active form (100). Being a Vitamin B3 derivative, NMN is naturally found 
abundantly in vegetables like cabbage, broccoli, and cucumbers and in fruits like avocados 
and tomatoes. The amount of NMN in various food sources has been summarised in Table 2 
(101). NMN absorption from food sources begins in the gut within 2-3 minutes where it 
undergoes dephosphorylation by CD73 to NR and enters the cells with the aid of nucleoside 
transporters. In the cells, NR is converted back to NMN to synthesize NAD+. Recently, a 
specific NMN transporter has also been identified in cells, encoded by the gene Slc12a8 that 
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is highly expressed in the small intestine. Knocking down this gene using lentiviruses in mice 
significantly reduced the plasma availability of NMN compared to the control. The Slc12a8 
NMN transporter has a molecular weight of nearly 90 kDa and is sodium ion dependent 
(100,102).  
 
                                                        
 
Figure 1.12: Structure of β-NMN. Nicotinamide mononucleotide has a phosphate group, 
Nicotinamide base and ribose sugar 
 
            NMN enhanced NAD+ levels and reversed impaired glucose tolerance and improved 
insulin sensitivity in rodent models of obesity and diabetes (103,104). NMN administration 
also prevented ischemic-reperfusion injury in the heart and cerebrum mediated by the sirtuin 
pathway (105,106). NMN supplementation has been successful in ameliorating alcoholic 
liver disease, acute kidney injury, retinal degeneration, cerebral haemorrhage and cognitive 
impairment in animal models (107).  Mitochondrial protein hyperacetylation has been 
implicated as a causative factor in heart failure. Elevation in the NADH/NAD+ ratio induces 
mitochondrial protein hyperacetylation and increases the sensitivity of the mitochondrial 
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permeability transition pore. NMN reverses hyperacetylation and normalizes the NAD+ 
redox balance in the heart (108). It also improved cardiac function and bioenergetics in a 
sirtuin dependent manner in rodent models of cardiomyopathy and so NMN has been 
evaluated as a potential drug in the treatment of cardiac dysfunctions (109).  
 
 
Table 2: Natural sources of NMN 
Source mg/100 g 
Broccoli 0.25 - 1.12 
Cabbage 0.0 - 0.90 
Avocado 0.36 - 1.60 
Cucumber 0.56 - 0.65 
Tomato 0.26 - 0.30 
Mushroom 0.0 - 1.01 
Raw beef 0.06 - 0.42 
Shrimp 0.22 
 
 
1.7 Rationale 
 
            Autophagic stimulation improves cardiac function by recycling the misfolded and 
dysfunctional proteins (110). Post-mitotic cells like cardiomyocytes rely highly on the 
lysosomal recycling mechanisms as they cannot simply be discarded when non-functional, 
owing to their limited potential to divide (111). Maintaining the autophagic flux in 
cardiomyocytes is hence beneficial to promote the longevity and functioning of these cells. 
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Stress triggers autophagic flux in cells to sustain the metabolic demand and organelle 
biosynthesis (112). Increased NAD+ synthesis maintains autophagic flux by activating sirtuin 
deacetylases (97). Sirtuins are implicated in aging, metabolism, and stress. The most 
extensively studied mammalian sirtuin, SIRT1, has been liked to transcriptional regulation 
and DNA repair as well (113). The deacetylase activity of sirtuins are attributed to their 
catalytic pocket having a conserved zinc tetra-thiolate motif (114). SIRT1 inhibition 
suppresses autophagy in cardiomyocytes and NAD+ enhances SIRT1 in the nucleus 
modulating the transcription of proteins regulating autophagy (115). SIRT1 expression is 
downregulated with DOX treatment and overexpressing this protein attenuates cardiac 
dysfunction (116). Our lab has previously reported that the NAD+ precursor, Nicotinamide 
Riboside (NR) prevented DOX induced accumulation of autolysosomes in mouse hearts and 
cultured cardiomyocytes by maintaining lysosomal acidification via NAD+/Sirt1 signalling 
(117). It is probable that the maintenance of autophagic flux by sirtuins in cardiomyocytes 
could be at least to some extent, attributed to the maintenance of lysosomal activity. Up-
regulation of the mitochondrial sirtuins has been demonstrated to accelerate the  impaired 
mitophagy by deacetylating the F0-F1 ATPase proton pump in mitochondria (118,119). F0-
F1 ATPase and the lysosomal V-ATPase are closely related in terms of structure and function 
and could have evolved from a common ancestor (120).  
Our lab has identified hyperacetylation of the d1 sub-unit of V0 domain (ATP6V0d1) in 
response to DOX treatment. It could be speculated that the protective role of NAD+ up-
regulation in DOX-induced cardiotoxicity could be in part via the deacetylation of the V-
ATPase pump subunits. NAD+ precursors like NMN are easily soluble and orally 
bioavailable and so have been widely researched on rodent models and have entered clinical 
trials as well (121). This study determines the potential and mechanism of NAD+ and its 
precursor, NMN, in preventing DOX-induced changes in lysosomal acidification and hence 
cardiotoxicity in an in-vitro model.       
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1.8 Hypothesis  
 
 I hypothesize that   
A) Doxorubicin increases lysosomal pH in H9c2 cells and induces cardiotoxicity. 
B) Boosting NAD+ using NMN will prevent DOX-induced increases in lysosomal pH 
and protect H9c2 cells from DOX toxicity. 
 
 
 
Figure 1.13:  Schematic illustration of Hypothesis. A) DOX treatment inhibits lysosomal 
acidification in H9c2 cells by depleting NAD+ levels and induce cardiotoxicity. B) Boosting 
NAD+ using NMN maintains the acidic lysosomal pH and protects H9c2 cells from DOX-
induced toxicity.  
 
 
A
 
B 
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1.9 Specific Aims 
 
1. Determine dose-dependent effect of DOX on H9c2 cells.  
2. Determine the effect of DOX on the lysosomal pH of H9c2 cells. 
3. Analyse the potential of NMN in preventing DOX- induced toxicity in H9c2 cells. 
4. Determine the mechanism by which NMN prevents DOX-induced increases in 
lysosomal pH.  
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Chapter 2 
 
2 Materials and Methods 
 
2.1 H9c2 cell culture 
 
            H9c2 (2-1) (CRL-1446) cells were procured from American Type Culture Collection 
(ATCC). Cells up to passage 15 were used for this study. The cells were grown in a culture 
flask incubated at 37℃ in a 5% CO2 humidified air atmosphere. The growth media used was 
high Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% heat-
inactivated fetal bovine serum (FBS), penicillin 100 IU/mL, and streptomycin 10 µg/mL. 
Sub-culturing was done every three days when confluency of 70-80% was attained. Briefly, 
the media in the flask was discarded and the cells were washed once with D-Hank’s solution 
(Table 3). The cells were then incubated with 0.25% Trypsin at 37℃ for 1-2 minutes. Fresh 
growth media containing 10% FBS was added to the flask to terminate the trypsinization 
process, and then cells were centrifuged at 125 x g for 5 minutes. The trypsin containing 
media was discarded and cells were suspended in fresh growth media and re-plated.  
 
Table 3: D-Hank’s Solution (1L) 
 
  
 
 
 
 
 
 
 
 
 
KCl 0.4 g 
KH2PO4 0.06 g 
NaCl 8 g 
D-Glucose 1 g 
Phenol red 0.012 g 
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2.2 Isolation and culture of neonatal cardiomyocytes  
 
            Primary neonatal cardiomyocytes were isolated from neonatal mice born within 24 
hours. Neonatal mice were wiped with 75% alcohol and then killed by decapitation. The 
chest was cut open at the sternum and the hearts were harvested into D-Hank's solution 
(Table 1) in a 50 mL tube. The hearts were rinsed in D-Hank's solution twice to remove the 
blood. Each heart was then divided into 5–6 pieces using a surgical blade and then rinsed 
again in D-Hank's solution. It was then subjected to the following 3 rounds of digestion; 
 (1) Heart sections were incubated in Liberase Blendzyme (2.5 mg/mL, Roche Applied 
Science) for 10 minutes at 37°C in a water bath and the supernatant was discarded.  
(2) The sections were again incubated in fresh Liberase Blendzyme solution at 37°C for 15 
min with gentle swirling every 5 min. After 15 min, the heart sections were minced to isolate 
the cardiomyocytes completely. The supernatant containing isolated cardiomyocytes was 
collected and the digestion was terminated by adding the culture medium, DMEM, 
supplemented with 10% new-born calf serum (NBCS). 
(3) The precipitate was again incubated with fresh Liberase Blendzyme and the digestion 
procedure was repeated.  
The supernatant was then pooled with the earlier one and centrifuged at 200 x g for 5 
minutes. The precipitate containing the isolated cardiomyocytes were resuspended in 10% 
NBCS supplemented DMEM. The cells were then seeded in a culture plate and placed in a 
CO2 incubator at 37°C for 120 minutes which allowed fibroblasts to adhere to the plate. After 
fibroblast adherence, cardiomyocytes were collected and counted. The cardiomyocytes were 
then seeded into a culture plate, coated with 1% gelatin and incubated in a CO2 incubator at 
37°C. The cardiomyocytes were utilized for experiments after 18 hours. The purity of 
neonatal cardiomyocytes was characterized by the staining for troponin and was more than 
95%. 
 
 
 
 
 
38 
 
2.3 Doxorubicin Cardiotoxicity- in vitro experimental model 
 
            H9c2 is an adherent cell line derived from the subclone of the ventricular part of the 
embryonic BD1X heart tissue of Rattus norvegicus and exhibits skeletal and cardiac muscle 
properties. It is a cell model used as an alternative for cardiomyocytes (122). H9c2 cells and 
neonatal cardiomyocytes were seeded in multi-welled culture plates at densities required for 
the assays and incubated at 37℃ in a 5% CO2 humidified air atmosphere. When desired 
confluency was attained (12-18 hours), cells were treated with NMN or NAD+ for 24 hours 
followed by DOX/Bafilomycin A/DOX-Bafilomycin A treatment for further 24 hours. 
Control cells were supplemented with fresh growth media and were devoid of any treatment 
throughout the duration of experiment.   
 
 
Figure 2.1: Schematic representation of the in vitro model used for study. 
 
2.4 CCK-8 Assay 
 
            Cell counting kit-8 (CCK-8) (Dojindo Molecular Technologies, Inc), a colorimetric 
assay, was used to determine the cell viability. The water-soluble tetrazolium salt, WST-8, is 
reduced by the dehydrogenases in living cells to a yellow colour formazan dye which is 
measured at an absorbance of 450 nm. H9c2 cells were seeded in a 96-well plate at a density 
of 10,000 cells per well. After treatment with various drugs, 10 µL of CCK-8 solution, 
provided by the manufacturer, was added to each well. The plate was incubated at 37°C for 
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1-4 hours. The absorbance was measured at 450 nm using iMark™ Microplate Absorbance 
Reader (Bio-Rad Laboratories Inc). The intensity of the yellow dye is directly proportional to 
the number of living cells. Percentages of viable cells were calculated using the formula: 
                 Cell viability % = Abs450 sample – Abs450 blank    X  100 
                                                Abs450 control - Abs450 blank  
 
 
2.5 Lactate Dehydrogenase Release Assay 
 
            Lactate Dehydrogenase (LDH) is soluble enzyme released from cells due to 
compromised cell membrane integrity. LDH enzymatically converts iodonitrotetrazolium to a 
red coloured formazan dye which can be detected using a colorimetric assay at an absorbance 
of 490 nm. The amount of LDH release is directly proportional to cell damage. LDH-
Cytotoxicity Colorimetric Assay Kit (Takara Bio Inc) was used to detect the activity of LDH 
released from H9c2 cells following treatment. The supernatant was collected in clear optical 
96-well microtiter plates and incubated for 30 minutes at room temperature with the reaction 
mixture containing catalyst and dye solution provided by the manufacturer. The reaction was 
stopped using 1N HCl and the absorbance was measured at 490 nm using iMark™ 
Microplate Absorbance Reader (Bio-Rad Laboratories Inc). 
 
2.6 Caspase-3 Activity 
 
            Caspase-3 belongs to the family of Cysteine-aspartic acid proteases and activation of 
the enzyme is required for apoptotic cell death. Activated caspase-3 in cell lysates cleaves the 
peptide substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) 
and releases fluorescent 7-amino-4-methylcoumarin (AMC) which can be detected at 
excitation and emission wavelengths of 360 and 460 nm, respectively. Caspase-3 activity in 
H9c2 cells was determined using the following protocol. Briefly, the cells were lysed using 
ice-cold lysis buffer (Table 4) and the cell lysates were centrifuged at 10,000 x g for 10 min 
at 4 °C. The supernatant was collected, and the protein concentration was measured using DC 
protein assay based on manufacturer’s protocol (Bio-Rad Laboratories Inc). 100μg protein 
was incubated with caspase-3 substrate Ac-DEVD-AMC and Ac-DEVD-AMC in the 
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presence of inhibitor AC-DEVD-CHO diluted in assay buffer (Table 4) at 37°C for 2 hours. 
Caspase-3 cleaves the substrate Ac-DEVD-AMC and releases chromophore AMC which can 
be detected by a fluorescence spectrophotometer with excitation of 355 nm and emission of 
460 nm.  
 
                             
                                              
Table 4: Lysis/Assay Buffer (100mL) 
Reagent Lysis Buffer Assay buffer 
HEPES (1 M, pH=7.4) 5 mL 5 mL 
CHAPS 0.1 g 0.1 g 
NaCl - 585 mg 
DTT (1 M) 500 µL 1 mL 
EDTA (0.5 M) 20 µL 200 µL 
NP-40 100 µL - 
Glycerol - 10 mL 
H2O 94.4 mL 83.8 mL 
 
 
2.7 Lysosomal pH measurement 
             
           Changes in lysosomal pH were measured using LysoSensor yellow/blue DND-160 
(Invitrogen). This dye imparts yellow fluorescence in acidic environments and blue 
fluorescence in neutral pH in living cells. The ratio of emission at 460 and 535 nm was used 
to interpret the pH. H9c2 cells were seeded in 96-well black clear bottom sterile plates at a 
density of 5000 cells per well. After treatment, the cells were incubated with the dye (1 µM) 
for 5 minutes at 37℃. The fluorescent signals were determined using a Spectra Max M5 
Multi Mode Microplate Reader with excitation of 340 nm. The ratio of emission, 460/535 
nm, was then calculated for each sample. 
 
 
 
41 
 
2.8 Co-immunoprecipitation (co-IP) and Western Blot Analysis 
 
            Co-immunoprecipitation was done to pull down the acetylated proteins from neonatal 
cardiomyocytes following DOX and NMN treatments. Cells were lysed using the lysis buffer 
(Table 4) and disrupted by ultrasonication and centrifuged at 10,000 x g for 10 minutes at 
4℃. Protein was quantified using DC protein assay (Bio-Rad Laboratories Inc) and 400 µg of 
protein was subjected to immunoprecipitation. Briefly, Anti-acetyl Lysine antibody (abcam) 
was used to pull down the proteins using Dynabeads™ Protein G Immunoprecipitation Kit 
(Invitrogen) following the manufacturer’s instructions. The protein was then eluted from the 
beads using the elution buffer supplied in the kit and subjected to SDS- polyacrylamide gel 
electrophoresis followed by western blot analysis.   
             The immunoprecipitated protein was mixed with 6X loading buffer (Table 5) in a 
microtube and incubated at 70℃ for 10 minutes on a dry bath for denaturing. The protein was 
then subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
using a 4% stacking gel (Table 6) and 12% resolving gel (Table 7) using a BIO-RAD Mini-
PROTEAN system. 30 µL of proteins were added to the wells of the gel and resolved at 
100V with in-house running buffer (Table 8) till the running front reached the end of the gel. 
 
                                          
Table 5: 6X Loading Buffer (100 mL) 
Tris-HCl (1M, pH 6.8) 37.5 mL 
SDS 6 g 
Bromophenol blue 30 mg 
Glycerol 48 mL 
β-Mercaptoethanol 9 mL 
H2O 5.5 mL 
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Table 6: 4% Stacking gel (6 mL) 
H2O 4.10 mL 
30% Acrylamide 1 mL 
Tris (1.5M, pH 6.8) 0.75 mL 
10% SDS 60 µL 
10% Ammonium Persulphate 60 µL 
TEMED 6 µL 
 
 
                                           
Table 7: 12% Resolving Gel (20mL) 
 
 
 
 
 
 
 
 
                                          
Table 8: Running Buffer pH 8.3 (1L) 
Tris Base 3.03 g 
Glycine 14.41 g 
SDS 1 g 
H2O 1 L 
β-Mercaptoethanol 9 mL 
 
H2O 4.10 mL 
30% Acrylamide 8 mL 
Tris (1.5M, pH 8.8) 7.5 mL 
10% SDS 200 µL 
10% Ammonium Persulphate 200 µL 
TEMED 8 µL 
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           The proteins were then transferred from the gel on to a poly vinyl difluoride (PVDF) 
membrane (Froggabio) by tank blotting in ice-cold transfer buffer (Table 9) at 25 V for 15 
hours using the Bio-Rad Mini Trans-Blot electrophoretic transfer cell. The membrane was 
then blocked using 5% non-fat milk (Bio-Basic) in TBST (Table 10) at room temperature for 
1 hour. After blocking, the membrane was incubated overnight at 4℃ with primary antibody 
at manufacturer recommended dilution dissolved in 5% BSA. The membrane was then 
washed 3 times with TBST for 10 minutes each followed by incubation with secondary 
antibody dissolved in 5% non-fat milk in TBST for 1 hour at room temperature. After 
washing the membrane again 3 times for 10 minutes each in TBST, the proteins on the 
membrane were visualised using a chemiluminescence detection system using enhanced 
chemiluminescence reagent (Table 11). 
                                                    
Table 9: Transfer Buffer (1L) 
Tris base 3.03 g 
Glycine 14.41 g 
Methanol 200 mL 
H2O 800 mL 
 
 
                                                     
Table 10: TBST pH 7.6 (1L) 
Tris base 2.42 g 
NaCl 8 g 
H2O 1000 mL 
Tween 20 1 mL 
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Table 11: Enhanced Chemiluminescence (ECL) Reagent (200mL) 
Component Reagent A Reagent B 
Tris-HCl (1M, pH 8.5) 100 mL 100 mL 
Coumaric acid (90 mM) 440 µL - 
Luminol (250mM) 1 mL - 
H2O2 - 60 µL 
 
 
 
2.9 Statistical Analysis 
 
            Statistical Analysis was done using Graphpad Prism software version 6.0. All data 
were presented as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) 
was used for analysing the results. Post-hoc comparisons were done using Tukey HSD or 
Dunnett’s Test as appropriate. A value of P < 0.05 was considered statistically significant. 
The test used for each experiment has been mentioned in the figure legend.  
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Table 12: Reagent Information 
Reagent Manufacturer 
 
Cat # 
DMEM Gibco, USA 11995-065 
DMEM Wisent Inc, Canada 319010CL 
HI FBS Gibco, USA 12484-028 
Penicillin-Streptomycin Gibco, USA 15140-122 
Trypsin-EDTA Gibco, USA 25200-056 
Liberase Blendzyme Roche Applied Science, 
Switzerland 
05401151001 
NBCS Gibco, USA 26010-074 
Gelatin Sigma, USA G9382 
 
Triton X-100 Sigma, USA  T9284 
NaOH VWR, USA  BDH7222-1 
Tris Bio Basic, Canada TB0196 
HCl Sigma, USA HX0603-4 
KCl Sigma, USA  PX1405-1 
KH2PO4  
 
Bio Basic, Canada PB0445 
NaCl  
 
Bio Basic, Canada DB0483 
D-Glucose  
 
Bio Basic, Canada GB0219 
Phenol red  
 
Sigma, USA P5530 
SDS  
 
Sigma, USA L3771 
Bromophenol Blue  
 
Sigma, USA 20017 
Glycerol  
 
Sigma, USA G5516 
β-Mercaptoethanol  
 
Sigma, USA 444203 
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Acrylamide Bio Basic, Canada AB1032 
APS Bio Basic, Canada AB0072 
TEMED Bio Basic, Canada TB 0508 
Glycine Bio Basic, Canada GB0235 
Methanol VWR, USA BDH1135-4LP 
Coumaric acid Sigma, USA C9008 
Luminol Sigma, USA A8511 
HEPES Bio Basic, Canada) HB0264 
CHAPS Bio Basic, Canada) CD0110 
DTT Bio Basic, Canada DB0058 
NP-40 Sigma Sigma, USA 13021 
Na2HPO4 Sigma, USA S0876 
 
β-NMN Apex Bio, USA B7878 
NAD+, free acid Calbiochem, Japan 481911 
Bafilomycin A Apex Bio, USA A8627 
Doxorubicin Hydrochloride Mylan, USA 67457-436-50 
EDTA Sigma, USA E5134 
 
             
 
Table 13: Antibody Information 
Antibody Manufacturer Cat# Dilution 
Anti-ATP6V0D1 Abcam, USA ab202897 
 
1:1000 
Anti-Acetyl Lysine Abcam, USA ab22550 
 
1:1000 
Anti-GAPDH Santa Cruz 
Biotechnology, USA 
sc-25778 1:1000 
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Chapter 3 
3 Results 
 
3.1 DOX induces dose-dependent toxicity in H9c2 cells 
 
            The toxic effects of DOX on H9c2 cells have been reported from our lab and authors 
elsewhere (117,123,124). Dose-dependent toxicity along with increased oxidative stress and 
autophagic flux impairment have been confirmed by these authors. To confirm the toxic 
effect of DOX on H9c2 cell viability and to determine the dose for further experiments, cells 
were seeded in 96-well sterile plates at a density of 1000 cells per well. After 24 hours, the 
cells were treated with DOX at concentrations of 0.5, 1, 2 and 5 µM. Control cells were left 
untreated. About ~75% of cells were found to be viable with 0.5 µM DOX. 1 µM DOX 
reduced the number of viable cells by nearly 50%. Less than 30% cells survived with 2 and 5 
µM DOX treatment for 24 hours. As shown in Figure 3.1, DOX reduces cell viability in a 
dose-dependent manner. As mentioned earlier, DOX has high affinity towards mitochondria 
in cardiomyocytes and 0.5- 1 µM has been considered as clinically relevant plasma 
concentrations where the mitochondrial accumulation is around 50 -100 µM (125).  
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Figure 3.1: DOX treatment decreased H9c2 cell viability in a concentration-dependent 
manner. H9c2 cells were cultured in 96-well plates for 24 hours. The cells were then 
incubated with DOX at concentrations of 0.5, 1, 2 and 5 µM or left untreated for another 24 
hours. Cell viability was assessed using CCK-8 method. One-way ANOVA analysis followed 
by Dunnett’s test was used to compare groups (n= 3 independent experiments) (*P<0.05 
versus control) 
 
 
 
 
 
 
 
 
* 
* 
* 
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3.2 DOX increases LDH release in H9c2 cells 
 
            LDH is a stable cytoplasmic enzyme released into the cell culture medium upon 
plasma membrane damage. H9c2 cells were seeded in 24-well plates and incubated for 24 
hours. The growth media was replaced with DOX containing culture media at concentrations 
of 1, 2 and 5 µM and incubated for another 24 hours. Control cells were left untreated. The 
media containing LDH was collected and incubated with an equal volume of reaction mix 
containing the catalyst and dye solution from the LDH-Cytotoxicity Colorimetric Assay Kit 
(BioVision Incorporated). The LDH enzyme in the media oxidizes the lactate component of 
the catalyst to pyruvate which in turn reacts with the tetrazolium salt of the dye solution 
forming a red coloured formazan dye. This water-soluble formazan dye was detected by a 
spectrophotometer at 490nm which corelates with the LDH activity in the cells. DOX at all 
the three concentrations increased the LDH activity by around 0.3-fold to 0.5-fold as seen in 
Figure 3.2. The LDH release in cells treated with 1 and 2 µM DOX were almost the same and 
5 µM DOX showed a slightly higher increase in the enzyme activity compared to the lower 
concentrations.  
 
 
 
 
 
 
50 
 
         
C
O
N
TR
O
L
D
O
X
 1
M
D
O
X
 2
M
D
O
X
 5
M
0.0
0.6
1.1
1.6
L
D
H
 R
e
le
a
s
e
(F
o
ld
 c
h
a
n
g
e
s
)
 
Figure 3.2: DOX treatment increased the LDH release in H9c2 cells. H9c2 cells were 
treated with DOX at concentrations of 1, 2 and 5 µM for 24 hours or left untreated. LDH 
release was measured. One-way ANOVA analysis followed by Dunnett’s test was used to 
compare groups (n= 3 independent experiments) (*P<0.05 versus control) 
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3.3 DOX treatment increases caspase-3 activity in H9c2 cells 
 
            Caspase-3 activation could lead to breakdown of myofibrillar proteins and contractile 
dysfunction even before cell death in cardiomyocytes (126). H9c2 cells were seeded in 24-
well plates at a density of 1 x 105 cells per well and incubated for 24 hours. The culture media 
was replaced with DOX containing culture media at concentrations of 1 and 2 µM and 
incubated further for 24 hours. Control cells were left untreated. Caspase -3 activity was 
assessed in the cells. DOX treatment at 1 and 2 µM increased the caspase-3 activity in H9c2 
cells by more than 6-fold and 7.5-fold, respectively (Figure 3.3). 
         Since the moderate injury for H9c2 cells was with 1μM DOX, when cell viability 
declined about 50% and caspase 3 activity and LDH release significantly increased, this dose 
was used to treat H9c2 cells in the subsequent experiments to generate the in vitro 
doxorubicin-induced toxicity model. Further, DOX treatment at 1 µM for 24 hours has been 
shown to induce autophagic impairment in cardiomyocytes resulting in the accumulation of 
ubiquitinated proteins as well (127). 
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Figure 3.3: DOX treatment increased the caspase-3 activity in H9c2 cells. H9c2 cells 
were incubated with DOX at concentrations of 1 and 2 µM for 24 hours. Control cells were 
left untreated. One-way ANOVA analysis followed by Dunnett’s post hoc test was used to 
compare groups (n=3 independent experiments) (*P<0.05 versus control) 
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3.31 DOX induces morphological alterations in H9c2 cells 
 
            Normal H9c2 cells are spindle-to stellate-shaped and can be mono- or multi-nucleated 
(128). H9c2 cells were incubated with 1 µM DOX for 24 hours and the morphological 
changes were examined. Changes in the structure of H9c2 cells were observed along with 
cytoplasm vacuolation (Figure 3.4).  
 
                      
                         Control                                                                 DOX (1 µM) 
Figure 3.31: DOX induces morphological alteration in H9c2 cells. H9C2 cells were 
treated with 1 µM DOX for 24 hours. The morphological changes were examined.  
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3.4 DOX treatment prevents lysosomal acidification in H9c2 
cells 
 
            Efficient lysosomal functioning is enabled with the support of over 60 hydrolytic 
enzymes within the organelle. These enzymes require an acidic pH of 4.5-5 for the enzymatic 
breakdown of the cellular debris within the lysosomes. The proton pump V-ATPase pumps 
H+ ions into the lysosomal lumen and maintains the pH within the organelle. Lysosomal 
abnormalities involving dysfunctional hydrolytic enzymes have been implicated in multiple 
cardiovascular disorders (51). H9c2 cells were incubated with 1 µM DOX and 100 nM 
Bafilomycin A (BafA) for 24 hours. The control cells were untreated. The changes in 
lysosomal pH were measured using LysoSensor yellow/blue DND-160 (Invitrogen). This 
ratiometric dye has dual excitation and emission characteristics and this property was 
exploited for investigating the lysosomal pH as described in the methods section. 
Bafilomycin A was employed as a positive control for the experiment. It is a potent V-
ATPase inhibitor and impairs autophagy by preventing lysosomal acidification. DOX altered 
the lysosomal pH of H9c2 cells compared to the control (Figure 3.4). The changes in 
lysosomal pH in response to DOX treatment were similar to the changes in Bafilomycin A 
treated cells.  
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Figure 3.4: DOX treatment altered the lysosomal pH by preventing acidification in 
H9c2 cells. H9c2 cells were treated with DOX (1 µM) and Bafilomycin A (BAF) (100 nM) 
for 24 hours. Control cells were left untreated. The lysosomal pH was determined based on 
460/535 ratio. One-way ANOVA analysis followed by Tukey post hoc test was used to 
compare groups (n= 10) (*P<0.05 versus control; ns-not significant) 
 
 
 
 
 
 
* 
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3.5 NAD+ and its precursor NMN prevents DOX-induced 
toxicity in H9c2 cells  
 
            Declined NAD+ levels are observed in the heart of rodent models of dilated 
cardiomyopathy in which NAD+ precursor supplementation improves cardiac function by 
stabilizing the myocardial NAD+ levels (129). Systemic NMN administration has been 
reported to up-regulate the NAD+ levels in the pancreas, heart, skeletal muscle and liver of 
rodents under pathological conditions (92). DOX treatment reduces the NAD+ content in 
cardiomyocytes. Previous work from our lab has also shown that pre-incubation with NAD+ 
precursors enhances the NAD+ levels in DOX-treated cardiomyocytes (117). Based on our 
experiments in the lab and literature review, 1mM concentration of NMN and NAD+ was 
used for assessing the protection imparted by these drugs in the in vitro model of DOX-
induced cardiotoxicity (130).  
 
3.5.1 NMN and NAD+ prevents DOX-induced increases in LDH 
release 
 
             H9c2 cells were per-incubated with NMN/NAD+ (1 mM) for 24 hours prior to DOX 
(1 µM) treatment. Cells were also treated with NMN/NAD+ alone and control cells were 
untreated. LDH release was examined in the cells as it is a major index of cell injury. NMN 
and NAD+ pre-incubation prevented DOX-induced increases in LDH release by nearly 0.4-
fold and 0.5-fold, respectively. NMN and NAD+ alone did not show much effect on H9c2 
cells compared to the control (Figure 3.5a and 3.5b). 
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Figure 3.5: LDH release in (a) DOX, NMN and NMN-DOX treated and (b) DOX, NAD 
and NAD-DOX treated H9c2 cells. One-way ANOVA analysis followed by Tukey post hoc 
test was used to compare groups (*P<0.05 versus control; **P<0.05 versus DOX) 
(a) 
* 
** 
* 
** 
(b) 
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3.5.2 NMN and NAD+ prevents DOX-induced increase in 
caspase-3 activity 
 
             It has been observed that DOX treatment increases the caspase-3 activity in H9c2 
cells. Here, caspase-3 activity was measured in H9c2 cells treated with NMN or NAD+ prior 
to DOX treatment. Compared to the DOX-treated group, NMN/NAD+ pre-incubation prior to 
DOX, significantly reduced the caspase-3 activity (Figure 3.6 and 3.7). 
                        
Figure 3.6: NMN prevents DOX-induced increases in caspase-3 activity in H9c2 cells. 
Caspase -3 activity in DOX, NMN and NMN-DOX treated H9c2 cells. One-way ANOVA 
analysis followed by Tukey post hoc test was used to compare groups (n=5) (*P<0.05 versus 
control; **P<0.05 versus DOX) 
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Figure 3.7: NAD+ prevents DOX-induced increases in caspase-3 activity in H9c2 cells.  
Caspase-3 activity in DOX, NAD and NAD-DOX treated H9c2 cells. One-way ANOVA 
analysis followed by Tukey post hoc test was used to compare groups (n=5) (*P<0.05 versus 
control; **P<0.05 versus DOX). 
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3.5.3 NMN and NAD+ increases the viability of DOX-treated 
H9c2 cells  
 
            NAD+ enhancement attenuated DOX-induced decrease in cell viability. There was 
nearly 50-80% increase in the number of viable cells after NMN/NAD+ pre-incubation prior 
to DOX treatment compared to the cells treated with DOX alone (Figure 3.8 and 3.9). 
Upregulating NAD+ levels in H9c2 cells improved the cell viability and decreased LDH 
release and caspase-3 activity, thereby protecting the cells from the deleterious effects of 
DOX. Supplementing NAD+ in H9c2 cells is therefore a good strategy to replenish the DOX 
depleted cellular pools and protect cells from toxicity. 
 
 
                        
Figure 3.8: NMN increased viability of DOX-treated H9c2 cells. Cell viability was 
assessed in H9c2 cells treated with DOX and NMN-DOX. Control cells were untreated. One-
way ANOVA analysis followed by Tukey post hoc test was used to compare groups (n= 3) 
(*P<0.05 versus control; **P<0.05 versus DOX) 
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Figure 3.9: NAD+ increased viability of DOX-treated H9c2 cells. Cell viability was 
assessed in H9c2 cells treated with DOX and NAD-DOX. Control cells were untreated. One-
way ANOVA analysis followed by Tukey post hoc test was used to compare groups (n= 3 
independent experiments) (*P<0.05 versus control; **P<0.05 versus DOX) 
                           
 
 
 
 
 
 
 
 
* 
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3.6 NMN and NAD+ prevents DOX-induced changes in 
lysosomal pH  
 
            Since DOX also altered to the lysosomal pH of H9c2 cells apart from being toxic, 
NAD+ upregulation in preventing the pH increase was examined. The pH changes were 
measured using the LysoSensor probe described earlier. Both NMN and NAD+ treatment 
prior to DOX incubation prevented the pH alterations (Figure 3.10 and 3.11). Statistically, pH 
of the NMN/NAD+ pre-incubated cells did not differ significantly from the control cells.  
 
                           
Figure 3.10: NMN prevented DOX-induced pH changes. H9c2 cells pre-treated with 
NMN (1 mM) for 24 hours prior to DOX treatment (1 µM) (24 hours). Control cells were left 
untreated. The lysosomal pH was determined based on 460/535 ratio. One-way ANOVA 
analysis followed by Tukey post hoc test was used to compare multiple groups (n= 10) 
(*P<0.05 versus control; **P<0.05 versus DOX) 
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Figure 3.11: NAD+ prevented DOX-induced pH changes. H9c2 cells pre-treated with 
NAD+ (1 mM) for 24 hours prior to DOX treatment (1 µM) (24 hours). Control cells were 
left untreated. One-way ANOVA analysis followed by Tukey post hoc test was used to 
compare multiple groups (n= 10) (*P<0.05 versus control; **P<0.05 versus DOX). 
 
 
 
 
 
 
 
* 
** 
 
64 
 
3.7 V-ATPase inhibitor, Bafilomycin A prevents NMN/NAD+ 
imparted protection against DOX cardiotoxicity 
 
            The V-ATPase inhibitor, Bafilomycin A, was used as a pharmacological tool to 
confirm the role of V-ATPase pump in DOX cardiotoxicity. Both BAF and DOX had been 
toxic to H9c2 cells and had induced pH alterations. DOX has already been reported to 
prevent the autophagic flux in cardiomyocytes by preventing acidification of lysosomes (52) 
and it had to be confirmed in the in vitro model used for this study as well.  
 
3.7.1 Bafilomycin A prevents NMN/NAD+ induced decreases in 
LDH release in DOX-treated H9c2 cells 
 
            H9c2 cells were pre-incubated with NMN/NAD+ (1 mM) for 24 hours and then treated 
with DOX (1 µM) and BAF (1 nM) for another 24 hours. LDH release was measured in the 
cells as described earlier. BAF treatment further increased the LDH release in H9c2 cells 
when compared to cells treated with DOX alone. The protective effect of NMN and NAD+ 
were abolished by the V-ATPase inhibitor (Figure 3.12 and 3.13). 
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Figure 3.12: Bafilomycin A prevented NMN induced decreases in LDH release in DOX-
treated H9c2 cells. LDH release in DOX, NMN, NMN-DOX, NMN-DOX-BAF treated 
H9c2 cells. One-way ANOVA analysis followed by Tukey post hoc test was used to compare 
groups (n=6) (*P<0.05 versus control; **P<0.05 versus DOX; ***P<0.05 versus NMN-
DOX) 
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Figure 3.13: Bafilomycin A prevented NAD+ induced decreases in LDH release in DOX-
treated H9c2 cells. LDH release in DOX, NAD, NAD-DOX and NAD-DOX-BAF treated 
H9c2 cells. One-way ANOVA analysis followed by Tukey post hoc test was used to compare 
groups (n=6) (*P<0.05 versus control; **P<0.05 versus DOX; ***P<0.05 versus NMN-
DOX) 
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3.7.2 Bafilomycin A prevents NMN/NAD+ induced protection 
against alterations in lysosomal pH in DOX-treated H9c2 cells 
              
Whether NAD+ imparted protection against lysosomal pH changes was via the V-ATPase 
pump related acidification was to be determined. H9c2 cells were pre-treated with 
NMN/NAD+ and then subjected to incubation with DOX (1 µM) and BAF (1 nM) for 24 
hours. BAF indeed prevented the protective effect of NMN and NAD+ in maintaining 
lysosomal pH (Figure 3.14 and 3.15). These results advocate that the protective mechanism 
of NAD+ could be by preventing the DOX-induced modifications of the lysosomal V-
ATPase pump.   
          
Figure 3.14: Bafilomycin A prevented NMN imparted protection against DOX-induced 
lysosomal pH alterations. H9c2 cells pre-treated with NMN (1 mM) for 24 hours prior to 
DOX, DOX/BAF treatment (24 hours). Control cells were left untreated. Control cells were 
left untreated. The lysosomal pH was determined based on 460/535 ratio. One-way ANOVA 
* 
** 
*** 
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analysis followed by Tukey post hoc test was used to compare groups (n= 10) (*P<0.05 
versus control; **P<0.05 versus DOX; ***P<0.05 versus NMN-DOX) 
 
            
Figure 3.15: Bafilomycin A prevented NAD+ imparted protection against DOX-induced 
lysosomal pH alterations. H9c2 cells pre-treated with NAD+ (1 mM) for 24 hours prior to 
DOX, DOX/BAF treatment (24 hours). Control cells were left untreated. The lysosomal pH 
was determined based on 460/535 ratio. One-way ANOVA analysis followed by Tukey post 
hoc test was used to compare groups (n= 10) (*P<0.05 versus control; **P<0.05 versus 
DOX; ***P<0.05 versus NAD-DOX) 
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3.8 NMN prevents hyperacetylation of ATP6V0d1 in DOX-
treated neonatal cardiomyocytes  
 
            Previous research from our lab had documented hyperacetylation of the d subunit of V0 
domain (ATP6V0d1) of the V-ATPase pump in response to DOX treatment in mouse models 
of DOX cardiotoxicity and neonatal cardiomyocytes. The protective effect of the NAD+ 
precursor, NMN in preventing hyperacetylation was hence worth investigating. This could be 
one of the mechanisms by which NAD+ upregulation protects cardiomyocytes against 
autophagic dysregulation by DOX. Neonatal cardiomyocytes were treated with NMN (1 mM) 
for 24 hours and then incubated with DOX (1 µM) for another 24 hours. Acetylated proteins 
were co-immunoprecipitated with anti-acetyl lysine antibody and separated on SDS-Page gel. 
After transferring on to PVDF membrane, the proteins were probed with anti-ATP6V0D1 
antibody to identify the acetylation levels on the cells. Coinciding with our earlier findings, 
DOX treatment induced hyperacetylation of ATP6V0d1. NMN treatment at 1 mM 
concentration for 24 hours prior to DOX incubation treatment prevented the hyperacetylation 
of ATP6V0d1 (Figure 3.16). 
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                                                          IP: anti-Acetyl lysine 
                                                          WB: anti-ATP6V0d1 
                                     acetylated ATP6V0d1 
                                     input ATP6V0d1 
                                    GAPDH 
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Figure 3.16: NMN prevented DOX-induced hyperacetylation of ATP6V0d1. 
(a) (Representative image) Neonatal cardiomyocytes were incubated with NMN prior to 
incubation with or without DOX. Control cells were left untreated. Co-immunoprecipitation 
of acetylated proteins followed by western blot analysis of ATP6V0d1 was done. (b) 
Quantification of proteins levels of acetylated ATP6V0d1 relative to ATP6V0d1. One-way 
ANOVA analysis followed by Tukey post hoc test was used to compare groups (n=3) 
(*P<0.05 versus CONTROL; **P<0.05 versus DOX) 
 N 
 
(a) 
(b) 
* 
** 
CONTROL DOX NMN NMN-DOX 
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Chapter 4 
 
4 Discussion, Limitations and Future Directions 
 
4.1 Discussion 
 
            Cancer is a growing burden on the Canadian health sector and the leading cause of 
death in the country. Several measures have been undertaken by the Government of Canada 
in addressing this issue and around $159 million have been invested in cancer research in the 
country in 2009-10 alone through the Canadian Institute of Cancer Research (131). The 
government has also invested $250 million to improve the quality of lives of Canadian 
Cancer patients and survivors through its initiative, Canadian Partnership Against Cancer, an 
independent not-for-profit organization. Despite of all these measures, nearly half of all 
Canadians are expected to develop cancer in their lifetime. 
            Doxorubicin has been a frontline drug in the treatment of cancer since decades and 
hence is a major player in the pharmaceutical industry in terms of revenue too. The major 
concern of this drug is its toxic effect on the heart posing acute and chronic threats. Though 
Doxorubicin cardiotoxicity has been widely studied, an effective treatment option is yet to be 
achieved. Cardiac toxicity associated with DOX administration is dependent on risk factors 
such as cumulative and age. Antioxidant supplementation along with DOX have so far been 
limited in preventing cardiotoxicity in the clinical scenario (132). Clinical studies on the 
effectiveness of beta-blockers like carvedilol, Angiotensin II receptor blockers (ARB) and 
Angiotensin converting enzyme (ACE) inhibitors, in preventing doxorubicin cardiotoxicity 
have resulted in mixed or no desired outcomes (133). Dexrazoxane, a bis-dioxopiperazine 
compound is co-administered with Doxorubicin to prevent cardiotoxic occurrences, but 
reduced chemotherapeutic efficacy and side effects like myelosuppression have been reported 
in patients (134). Effective treatment strategies in managing the toxic effects of DOX would 
open more room to exploit the therapeutic potential of the drug.  
            The role of autophagy in DOX cardiotoxicity has gained considerable interest in 
recent years. Stimulating basal autophagy by calorific restriction and mTORC inhibition has 
been demonstrated to reduce DOX toxicity in rodents. Also, interfering with the proteins 
involved in late autophagic machinery has been reviewed as a promising strategy and could 
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contribute in alleviating the complication (135). This study focuses on revealing the 
mechanisms of impaired lysosome acidification in cardiomyocytes causing autophagic 
disruption in response to doxorubicin treatment. A novel role of NAD+ precursor, NMN, in 
establishing the basal autophagic machinery in DOX treated cardiomyocytes by augmenting 
impaired lysosome acidification been proposed. This study establishes the defects induced by 
Doxorubicin on the lysosomal V-ATPase, the proton pump essential for regulating pH. 
Further, the therapeutic scope and mechanism of NMN, the NAD+ precursor in preventing 
Doxorubicin-induced autophagic dysregulation by establishing the lysosomal function has 
been evaluated. 
 
4.1.1 Doxorubicin induces toxicity and death in cardiomyocytes 
 
            In the clinical scenario, DOX induces cardiomyocyte death within hours of 
intravenous administration (136). Dose-dependent toxicity cardiotoxic effects of DOX have 
been established in this study on the rat myoblast cell line H9c2 and on human induced 
pluripotent stem cells-derived cardiomyocytes and adult cardiomyocytes by researchers 
elsewhere. Increases in the LDH release, DNA fragmentation and activation of caspases are 
observed in these cells (137,138).  
            Increased LDH activity is evident in human hearts with defects and end-stage failure 
and early interventions have been reported to improve the clinical outcomes of these patients. 
LDH is a sensitive method and an early biochemical indicator of myocardial complications. 
Plasma levels of LDH increase within 8-12 hours of cardiac injury, peaks in 2-3 days and 
remains elevated for 7-10 days. High serum LDH levels predicts short survival time in 
patients with multiple myeloma treated with a combinatorial Doxorubicin drug regimen 
(139–142). DNA fragmentation is a marker of apoptosis and increased levels of fragmented 
DNA are observed in cardiomyopathy which often transitions to heart failure. Oxidative 
stress induces high levels of DNA damage in patients with cardiovascular diseases (143,144). 
Caspases are cysteinyl aspartate specific proteases involved in the cleavage of several 
proteins propagating cellular homeostasis by inducing apoptosis, proliferation, and 
inflammation. These proteases are widely expressed, and 12 human caspases have been 
identified till date. Tightly regulated activation of caspases prevents premature cell death. 
Activation of caspases in the heart degrades the myofibrillar proteins such as actin and actinin 
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resulting in the impairment of the myofibrillar ATPase active and contractile dysfunction. In 
normal conditions, due to their limited proliferative capacity, only around 0.001-0.01% of 
cardiomyocytes undergo apoptosis. Caspase-3 is an executioner caspase directly cleaving the 
substrate proteins and promotes the downstream cascade of events in apoptosis. Caspase 
activation degrades autophagic proteins like Beclin-1, Atg5 and Atg7, impairing the 
autophagic machinery and converts pro-autophagic proteins to pro-apoptotic proteins, thereby 
triggering apoptosis (145). The myocardial cells exhibit a stage of interrupted apoptosis, 
where there is contractile dysfunction with increased caspase-3 activity but normal nuclei. 
This prolonged pre-death stage suggests that cells have the possibility to be rescued with 
restoration of myocardial function. (126,146–148). 
            Increased caspase-3 expression is found in the hearts with end-stage heart failure and 
ventricular arrythmias and considerable reduction of this protease is seen in patients with left 
ventricular assisted device (LVAD) support. Over-expressing cardiac specific caspase-3 in 
mice induced myofibrillar ultrastructural damages and lethality was also reported in caspase-
3 transgenic mice with increased infarct size when subjected to myocardial ischemia-
reperfusion injury (148). DOX treatment induces apoptosis in cardiomyocytes and rat cardiac 
ventricles by activating caspase-3 (149). In consistence with data published by peers, the 
present study also reports a dose-dependent increase in caspase-3 activity of H9c2 cells in an 
in vitro model of DOX cardiotoxicity. Although the exact mechanism of caspase-3 activation 
by DOX remains unclear, H2O2 induced ROS is predominantly considered as the mediator of 
caspase-3 activation in cardiomyocytes in contrast to caspase-3 activation mediated by p53 in 
tumour cells (150). 
 
4.1.2 Doxorubicin inhibits acidification and induces lysosomal 
dysfunction in cardiomyocytes 
 
             With high rates of oxygen consumption and aerobic respiration, the post-mitotic 
myocardial cells are highly susceptible to damage associated with pathological conditions 
such as aging and disease. Due to the lack of proliferative and renewal capacities, myocardial 
cells depend extensively on the intracellular recycling mechanisms for their survival. 
Lysosomes, being the key organelles demonstrating degradative and salvaging capabilities, 
are vital in preserving the viability of these cells. Autophagic clearance of damaged and 
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defective proteins and organelles in the cell carried out by lysosomes maintains 
cardiomyocyte homeostasis and longevity. Cells when subjected to stress, activate autophagy 
to get rid of the malfunctional cellular structures formed in response to various stimuli. 
Insufficient autophagy in stressed cells could result in the accumulation of ROS and 
induction of apoptosis. In cardiomyocytes, proper lysosomal function and autophagy is of 
utmost importance as the respiratory organelle mitochondria is actively functioning and often 
suffers from oxidative damage and should be recycled (50). Autophagic flux impairment has 
been implicated in doxorubicin cardiotoxicity and our lab has reported this previously. 
Increased steady-state LC3-II levels indicates activation of autophagic flux or downstream 
blockage of autophagic vacuole processing. Bafilomycin A, the inhibitor of late stage 
autophagy, increased the LC3-II protein levels in saline-treated cardiomyocytes. Compared to 
the saline-treated cells, Bafilomycin A treatment did not further increase the LC3-II protein 
levels in doxorubicin-treated cardiomyocytes suggesting a block in the autophagic flux (117).  
            The hydrolytic enzymes within the lysosomes are tightly regulated by the pH within 
the organelle. An acidic pH of 4.5-5 is essential for the enzymatic activity in the interior of 
lysosomes. The interior perimeter of the lysosome is protected from the attack from its own 
enzymes with the help of a glycocalyx lining. The pH gradient is generated and maintained 
with the help of protons pumped into the lysosomal lumen by the V-ATPase pump. ATP 
hydrolysis at the cytoplasmic V1 domain of V-ATPase imports protons via the membrane-
embedded V0 domain. The pumping mechanism is tightly regulated by the reversible 
assembly of the domains and has been described in detail in the first chapter. Disorders in 
lysosomal acidification have been implicated in several neurogenerative diseases, Crohn’s 
disease and lipotoxicity (151–153). Doxorubicin treatment inhibited the lysosomal 
acidification in neonatal rat ventricular myocytes resulting in the disruption of autophagic 
flux and accumulation of ROS (52), leading to cell death. 
            Using the V-ATPase inhibitor Bafilomycin A as a positive control, the lysosomal 
acidification defects in DOX-treated H9c2 cells have been established in this study. 
Compared to the control group, H9c2 cells incubated with Bafilomycin A and Doxorubicin 
showed similar alterations in lysosomal pH. The results obtained indicate that Doxorubicin 
inhibits V-ATPase, prevents the acidification of lysosomes, and impairs the autophagic 
machinery in cardiomyocytes. Since Bafilomycin A impaired V-ATPase activity partly by 
inhibiting the subunit c of V0 domain, DOX mediated inhibition of V-ATPase subunits was 
worth investigating. Preliminary results from an ongoing research in our laboratory have 
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indeed identified DOX mediated modification on the subunit d of the V-ATPase V0 domain. 
Interestingly, none of the other subunits from the V1 or V0 domains showed any alterations.   
4.1.3 NMN confers protection against Doxorubicin-induced 
toxicity and death in cardiomyocytes 
 
             NAD+ homeostasis in the cell is vital for regulating cellular bioenergetics as it is an 
important co-factor for many intracellular enzymatic reactions. Altered NAD+ homeostasis 
and depleted levels of NAD+ have been linked to aging and development of several diseases 
of the brain, heart, liver, skeletal muscle, kidney, and gut. Decreased levels of NAD+ have 
been linked to multiple cardiac pathologies. Overactivation of the NAD+ consuming 
enzymes in the heart leads to the depletion of the cofactor and affects the normal functioning 
of the cells in the organ. In cardiomyocytes too, as in other cells, NAD+ is critical for the 
maintaining the fuel oxidation. NAD+ gets reduced to NADH, which get re-oxidised in the 
mitochondria to produce ATP in a process termed as oxidative phosphorylation. This process 
generates about 95 % of the cardiac ATP content. The phosphorylated NAD+, NADP+, is an 
essential component in the pentose phosphate pathway generating NADPH and ribose 5-
phosphate. NADPH is involved in lipid biosynthesis and protects against ROS. In models of 
cardiac dysfunction, NAD+ supplementation using precursors re-establishes the depleted 
NAD+ pools and normalized the redox reactions in the cell (94,154).  
            The NAD+ precursor, NMN, have shown promising therapeutic effects on various 
cardiovascular complications. NMN prevented ischemic injury and increased sirtuin activity 
and vasodilatory function in rodent models of heart ischemia/reperfusion. This NAD+ 
precursor also showed potential to reverse left ventricular contractile dysfunction in animal 
models (94). Our lab has recently reported the protective effect of another NAD+ precursor, 
NR in ameliorating Doxorubicin-induced cardiotoxicity in mice via modulating the 
NAD+/SIRT1 pathway (117). This study for the first time demonstrates the potential of 
NMN in preventing toxic effects of Doxorubicin in an in vitro cell culture model. Both 
NAD+ and NMN improved the viability of H9c2 cells and prevented the increases in LDH 
release and caspase-3 activity. Based on the results from this study, NMN attenuated the cell 
damage in Doxorubicin treated cells and prevented cell death.  
            Orally administered NMN is rapidly absorbed and converted to NAD+ in peripheral 
organs and is retained longer in the body than other NAD+ intermediates (101). A clinical 
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trial to investigate the safety profile of NMN revealed no side effects up to single oral doses 
of 0.5 gram/day in healthy men. NMN was effectively metabolised and did not cause any 
adverse clinical symptoms in the subjects. The biochemical analysis revealed normal ranges 
of serum creatinine, chloride, and blood glucose levels (155). Another clinical trial to 
investigate the effects of NMN on cardiometabolic functions are currently underway and is 
expected to be completed soon (156). Bioavailability and therapeutic value of NMN can 
hence be exploited and has the potential to be translated in mitigating Doxorubicin 
cardiotoxicity.  
 
 
4.1.4 NMN protects cardiomyocytes from Doxorubicin-induced 
alterations in lysosomal pH 
 
            As mentioned earlier, efficient lysosome functioning is critical in post-mitotic cells 
like cardiomyocytes. Insufficient autophagy in cardiomyocytes lead to the accumulation of 
defective organelles like mitochondria and damaged proteins in cell and contributes to the 
ROS generation leading to oxidative stress. Lysosomal acidification by V-ATPase is vital in 
maintaining autophagic flux. NR supplementation prevented lysosomal alkalinization in 
Doxorubicin- treated adult cardiomyocytes (117). The current study also validated the effects 
of NAD+ supplementation in preventing pH increases in cardiomyocytes in response to DOX 
treatment. Treatment with NMN blocked the effects of Doxorubicin on the lysosomal pH of 
H9c2 cells. NAD+ treatment also showed similar results suggesting the NMN mediated 
lysosomal pH preservation could be facilitated by the conservation of the NAD+ pool in 
H9c2 cells. Since lysosomal pH is maintained by V-ATPase activity, it is possible that NAD+ 
may veil the proton pump from the deleterious effects of Doxorubicin. Hence, we postulated 
that the hyperacetylation of the V-ATPase V0d subunit induced by Doxorubicin identified in 
our laboratory, could be prevented by NMN. 
4.1.5 Bafilomycin A abrogates the protective effects of NMN in 
Doxorubicin-induced cardiotoxicity 
 
            Doxorubicin inhibits lysosomal acidification in cardiomyocytes by inhibiting V-
ATPase and blocking proton transport (52). To clarify the role of V-ATPases in Doxorubicin 
mediated cardiotoxicity, Bafilomycin A, a specific V-ATPase inhibitor, was used to inhibit 
 
77 
 
the proton transport mechanism in H9c2 cells. NAD+ upregulation was unable to rescue the 
cells from lysosomal pH increases, when Bafilomycin A was incubated with Doxorubicin. 
The protection imparted by NMN in preventing lysosomal pH alterations in H9c2 cells were 
hence abrogated suggesting a modulatory role of NAD+ on the V-ATPase pump activity.  
            Bafilomycin A inhibits lysosomal acidification by binding to the c subunit of the V-
ATPase V0 domain and as mentioned earlier, we have preliminary results from our lab 
validating a similar modus operandi of Doxorubicin on the proton pump. Since NAD+ and 
NMN failed to protect the lysosomal pH of DOX-treated H9c2 cells in the presence of the V-
ATPase inhibitor, it was anticipated that NAD+ upregulation might be exerting its effects via 
modulating V-ATPase. 
 
4.1.6 NMN prevents hyperacetylation of the d subunit of V-
ATPase pump V0 domain 
 
            NMN supplementation restores the NAD+ levels and stimulates the activity of the 
NAD+ dependent lysine deacetylase SIRT1 in the heart. SIRT1 inhibitor splitomycin 
prevented the protective effects of NMN in heart ischemia-reperfusion injury justifying the 
role of SIRT1 pathway in NAD+ mediated cardio protection (130). Hyperacetylation of 
various autophagy related proteins and transcription factors including TFEB have been 
implicated in several cardiovascular complications. Activation of DNA repair enzymes like 
PARPs deplete the NAD+ reserves in the cells and constrain the deacetylation activity of 
sirtuins. Under normal physiological conditions, PARPs are also deacetylated and inhibited 
by sirtuins to preserve the NAD+ levels in cardiomyocytes. But damages to the DNA leads to 
NAD+ consumption due to PARP activation and inhibition of sirtuin activity (157). 
Doxorubicin induced epigenetic modifications such as DNA methylation and histone 
modifications exacerbate the toxic effects of the drug on cardiomyocytes by altering the gene 
expression (158).  Our lab has previously reported robust increase in p53 acetylation in 
cardiomyocytes treated with Doxorubicin. NAD+ supplementation prevented the acetylation, 
but this protective effect was abolished when the cells were co-incubated with the SIRT1 
inhibitor, EX-527, highlighting the role of NAD+ mediated deacetylation as a defensive 
phenomenon in Doxorubicin cardiotoxicity (117).  
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            In line with the ongoing research in our laboratory on DOX-induced cardiotoxicity, 
this study explored the potential of NMN assisted deacetylation mechanism on the DOX- 
induced hyperacetylation on the V-ATPase V0d1 subunit. Pre-incubating neonatal 
cardiomyocytes with NMN prevented hyperacetylation as evidenced by co-
immunoprecipitation and western blotting experiments. Thus, a unique role of the NAD+ 
precursor, NMN, was established in this study which could open doors for further meritorious 
investigations. Preventing the hyperacetylation of the V-ATPase d1 subunit is assumed to be 
a possible mechanism of NMN mediated inhibition of lysosomal pH increases in Doxorubicin 
treated cells.  
            The V-ATPase d subunit is ubiquitously expressed and links the proteolipid c ring of 
V0 and the central stalk of V1 (55). Subunit d is also hydrophilic and is located on the 
cytoplasmic side of the c ring. Binding sites for the D and F subunits of the V1 domain are 
present on subunit d and it is a vital protein of the V-ATPase rotary complex comprising of  
D, F and proteolipid ring (159).   Unless complexed with the V0 domain, d doesn’t bind to the 
D subunit of central stalk (60). During disassembly of the V-ATPase domains, subunit a 
separates from the V1 subunit and binds to d, preventing its rotation (58). Crystal structure 
and electron microscopic analysis suggests that the d subunit serves as a socket to attach 
central stalk subunits of V1 onto the V0 phospholipid ring, coupling the two domains (160). 
Subunit d dissociates from the membrane on treating with alkaline reagents such as Na2CO3 
or 5M urea and at a pH of 11.5 in in vitro experiments. Moreover, subunit d is the only 
component of V0 that is not an integral membrane protein (63). Based on all these literatures, 
it is logical to assume that subunit d is prone to acetylation modifications when cells are 
subjected to Doxorubicin treatment either directly by DOX/ROS or indirectly by 
NAD+/SIRT inhibition. 
 
4.2 Concluding Remarks 
 
            This study uncovers a novel role of NMN in establishing the basal autophagic 
machinery in DOX treated cardiomyocytes by improving impaired lysosome acidification. 
The d subunit of V-ATPase V0 sector is the only protein in the membranous domain of the 
proton pump to be localised to the periphery of the lysosomal membrane and could be prone 
to modifications by DOX directly or indirectly. It is an important regulator of proton 
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transport and hence hyperacetylation could account for DOX-induced lysosomal dysfunction 
in cardiomyocytes. Pre-incubation with the NAD+ precursor, NMN, averted hyperacetylation 
of the V-ATPase d subunit in DOX-treated cardiomyocytes. Also, NMN and NAD+ imparted 
protection to H9c2 cardiomyocyte cells from Doxorubicin toxicity by preventing cell injury 
and lysosomal pH alterations (Figure 4.1). Based on these findings and the safety profile of 
NMN, this molecule could be credibly considered as a beneficial drug in ameliorating 
Doxorubicin cardiotoxicity.   
 
 
 
Figure 4.1: Schematic illustration of the study. (A) Doxorubicin depletes the NAD+ 
content and stimulates hyperacetylation of ATP6V0d1 thereby preventing lysosomal 
acidification and inducing cardiomyocyte cell toxicity. (B) NAD+ precursor, NMN, 
supplements the NAD+ pools depleted by Doxorubicin and prevents the hyperacetylation of 
ATP6V0d1 and hence maintains acidic lysosomal pH and prevents cardiomyocyte cell 
toxicity. 
A 
 
B 
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4.3 Limitations 
 
            1) Direct evidence of NAD+ upregulation by NMN in H9c2 cells has not been 
included in this study. However, this has been reported by multiple researchers and our lab 
also has unpublished data of NAD+ upregulation by NMN in H9c2 cells.  
            2) This study has focussed on therapeutic scope of NMN in in vitro models of 
Doxorubicin cardiotoxicity. Though NMN has shown cardioprotective effects in in vivo 
models of cardiac complications and NR has shown potential in rodent models of 
Doxorubicin cardiotoxicity, additional studies are required for validating the protective 
effects of NMN in Doxorubicin cardiotoxicity. 
            3) Though pharmacological inhibitors such as Bafilomycin A, serves the purpose in 
providing mechanistic evidence of V-ATPase inhibition, genetic manipulations would have 
supported the claim further.  
            4) NMN indeed did prevent hyperacetylation of ATP6V0d1 and inhibited lysosomal 
pH increases in Doxorubicin treated cardiomyocytes, but other mechanisms of protection on 
lysosomal functioning and autophagic flux in Doxorubicin cardiotoxicity may exist which 
warrants further investigations. 
            5) Inclusion of in vitro lysosomal imaging techniques would have aided the intention 
of this study and would have spiked the visual interest of readers as well. 
 
4.4 Future Directions 
 
            NAD+ mediated protection in Doxorubicin cardiotoxicity is speculated to include the 
sirtuin pathway. Though our lab has reported the involvement of SIRT1 in the protective 
mechanism of NR in Doxorubicin cardiotoxicity using pharmacological inhibitors (117), we 
intent to further verify this, in the mechanism of protection imparted by NMN as well. 
Pharmacological interventions and genetic manipulations will be used to elucidate the role of 
sirtuins, particularly SIRT1, using in vitro and in vivo models of disease.  
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            Negative regulation of TFEB, the master regulator of lysosome biogenesis has been 
implicated in the progression of Doxorubicin cardiotoxicity (161). Acetylation of TFEB 
prevents its activation and stalls the synthesis of several proteins in the autophagic machinery 
(99). The role of NAD+ upregulation in augmenting TFEB function and lysosome biogenesis 
will be evaluated in future experiments.   
            The acetylation patterns on ATP6V0d1 in response to Doxorubicin treatment will be 
investigated using mass spectrophotometry. Individual site mutations will be generated at the 
identified acetylation sites through gene mutagenesis and the vital acetylation sites impacting 
the efficient functioning of V-ATPase will be explored. Using genetic manipulations, the role 
of ATP6V0d1 will be studied in in vivo models of Doxorubicin cardiotoxicity as well. 
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